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Abstract
“Proteomic and Metabolomic Analyses of Biological Systems with Liquid
Chromatography Tandem Mass Spectrometry and Ion Mobility Mass Spectrometry”
by Megan M. Maurer
Proteomic and metabolomic analyses provide information about altered metabolic
processes in plants and animals. This information can be used to assess the impact of
toxicant exposure or diseases on biological systems. In this dissertation, development of
an ion mobility spectrometry - mass spectrometry (IMS-MS) strategy has been evaluated
in addition to utilizing traditional liquid chromatography tandem mass spectrometry (LCMS/MS) techniques for metabolite and protein analysis. Traditional LC-MS/MS
techniques have been applied to the study of: 1) the molecular mechanisms responsible
for altered microvasculature function as a result of pulmonary TiO2 exposure in rats; and
2) the effectiveness of intracerebroventricular (ICV) injection of streptozotocin (STZ) to
mimic early metabolic changes found in tauopathies in mice exhibiting P301L or human
wild-type tau.
Inhalation exposure to TiO2 nanoparticles (NPs) has been shown to produce a
pulmonary inflammatory response, to induce oxidative and nitrosative biomarkers in the
systemic microcirculation, and to influence downstream microvascular dysfunction.
However, the molecular mechanisms relating pulmonary inflammation with the systemic
microvascular dysfunction in addition to differences in responses of vascular tissues have
yet to be fully elucidated. The first study examined plasma from rats exposed to TiO2
NPs. A total of 58 proteins were identified by at least 2 unique peptides and found in at
least 3 samples, and 23 metabolites were identified through ChemSpider matches and
filtered for endogenous compounds. The compounds were then analyzed by principal
component analysis (PCA) and 29 proteins and 18 metabolites were found to contribute
most to the separation in PC1. These proteins and metabolites were then input into
Ingenuity Pathway Analysis (IPA). IPA revealed 13 canonical pathways as being
significant (p ≤ 0.05) based on the input proteins, but none were found to be significantly
up or down regulated (z ≥ |2|) based on fold differences of the input proteins.
The second study examining plasma, aorta, and small resistance vasculature tissue
from rats exposed to TiO2 NPs was performed in order to gain further insight into the
pathway activation mechanisms as well as to determine if responses differ based on tissue
structural and functional differences. Congruent with the previous study, acute phase
response signaling, LXR/RXR activation, and FXR/RXR activation emerge as being
significant pathways (p ≤ 0.05) in the aorta and plasma; however, none were found to be
significantly up or down regulated (z > |2|). ILK signaling, D-myo-inositol (1,3,4)trisphosphate biosynthesis, and 1D-myo-inositol hexakisphosphate biosynthesis II
(mammalian) pathways are observed to be significant (p ≤ 0.05) in the vasculature, but
none were found to be significantly up or down regulated (z ≥ |2|).
P301L and human wild-type (WT) tau mice were administered an
intracerebroventricular (ICV) injection of control vehicle buffer (Veh) or streptozotocin
(STZ) to mimic early metabolic changes found in tauopathies, including Alzheimer’s
disease and frontotemporal dementia. Brain hemispheres were analyzed from 6 sample

cohorts: Control (CT)-Veh, CT-STZ, P301L-Veh, P301L-STZ, WT-Veh, and WT-STZ.
Bottom-up proteomic analyses were utilized to identify differentially abundant proteins
within the brain proteome and the biopathways altered as a result of ICV-STZ treatment.
An ANOVA was used to determine the top 50 significant proteins among the 6 sample
cohorts. Biopathway analysis of the top 50 proteins revealed 49 biological pathways as
being significant (p ≤ 0.05), but none were significantly up or down-regulated (z ≥ |2|)
among the cohorts. 14-3-3 Mediated Signaling was found to be the most significant
pathway among the cohorts. Protein Kinase A Signaling pathway was also found to be
significant and had an associated z-score, although it was not found to be significantly up
or down-regulated in any of the comparisons. Proteome and pathway changes were
observed as a result of ICV-STZ administration; however, none were found to be
significantly up or down-regulated.
LC-MS/MS is a widely used method for metabolite identification. However,
there are challenges with compound identification due to matrix effects, difficulty in
separating isomers and isobars, and long analysis times. IMS has proven to be useful in
separating isomer and isobar ions according to differences in mobilities through an inert
buffer gas. IMS coupled with MS also offers advantages in speed requiring a fraction of
the time used in condensed-phase separations. Despite such advantages, IMS-MS suffers
from decreased peak capacity relative to LC-MS/MS. The addition of gas-phase
hydrogen/deuterium exchange (HDX) to IMS-MS could allow for further differentiation
among compounds as there can be differences in the incorporation of deuterium.
Activating the ion to induce hydrogen/deuterium (HD) scrambling in the drift tube
followed by HDX has demonstrated deuterium uptake differences among different
species. In proof-of-principle experiments, these techniques are here shown to be highly
reproducible (drift time CVs <2.0% and isotopic pattern RMSDs of <1%) while
demonstrating an overall increase in peak capacity. Furthermore, this strategy is faster
than LC-MS/MS offering the potential for complete complex mixture analysis in as little
as 20 seconds.
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Chapter 1

Introduction

1

1.1 Introduction
Life has evolved complex biological processes, organizations, and functions
based on a hierarchy of genes, proteins, and metabolites.

Genes contain the long term

“data” storage of the system; however, genes can be activated, inactivated, or even
changed due to environmental response or random mutations [1]. Proteins, encoded by
genes, can be thought of as the short term “data” storage systems within the body.
Proteins respond to available resources and stimuli to drive metabolic processes within
the body. This includes acting as enzymes for catabolic and anabolic processes of
metabolites and activating and deactivating genes to induce or inhibit transcription of
messenger RNA (mRNA).

Metabolites not only act as building blocks for energy

consumption and energy storage, they also serve as messengers within the body to
promote activation and deactivation of proteins [1]. The interplay of this hierarchal
system helps an organism adapt to different stressors including disease and toxicants as
demonstrated in Figure 1.1. The result exposure to stressors can be measured as an
overall physiological outcome or the changes in organism on a molecular level [1].
By linking the physiological outcomes to operative underlying molecular
mechanisms, researchers can gain a better understanding of biological processes which
can lead to improved treatments. Furthermore, the information can assist policy makers
in making recommendations or enacting legislation to improve public health. There is a
myriad of analytical instrumentation available to study organisms on a molecular level.
Proteins and metabolites have been studied using instrumentation such as nuclear
magnetic resonance (NMR) spectroscopy [2–5], capillary electrophoresis (CE) [6–9],
liquid chromatography (LC) [10–13], CE with mass spectrometry (CE-MS)
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[14–

3

17], and LC-MS [18–21]. Gas chromatography (GC) has been used alone [22–25] and in
combination with MS [26–29] for metabolite analysis; however, it is not well suited for
protein or peptide analysis.
Each technique has its own advantages and disadvantages for comparative ‘omics
analyses. NMR is useful for determining structures of compounds and is inherently
quantitative; however, it lacks sensitivity and therefore is not appropriate for
determination of low abundance species (as reviewed in reference [30]). CE offers many
variations of the technique (e.g., zone electrophoresis, isoelectric focusing, gel
electrophoresis, and micellar electrokinetic chromatography), requires low volumes of
solvents, and it has also been coupled to mass spectrometers (as reviewed in reference
[31]). However, Joule heating and diffusion can decrease the resolution of CE [31]. GC
greatly improves signal-to-noise ratios, works well for volatile compounds, but
derivatization is often required for sample analysis and analysis of proteins or peptides is
not routine (as reviewed in reference [30]). LC also offers variations of the technique
[normal phase, reverse phase, hydrophobic interaction chromatography (HILIC), and ion
pairing], and recent reduction of column particle size has reduced the amount of solvents
required and analysis times (as reviewed in reference [30]). Additionally, LC works well
for many different compound classes [30]. Unfortunately, LC-MS techniques suffer from
matrix effects due to mobile phases or sample solvents and have difficulty separating
isobars and isomers (as reviewed in reference [19]). Furthermore, analysis times require
several minutes to hours for completion and there is run to run variation in compound
retention time [19].
For this work LC-MS/MS was selected as the primary means of protein and
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metabolite analysis due to its versatility with regard to the types compounds that can be
analyzed, and the availability of a LC system coupled to a high resolution mass
spectrometer (Q Exactive, Thermo Fisher, San Jose, CA). Bottom up proteomic and
metabolomics analyses by LC-MS/MS were used to determine what occurs at the
molecular level when rats are exposed to TiO2 nanoparticles (Chapters 2 and 3) and when
tau mice are intracerebroventricularly (ICV) administered streptozotocin (STZ, Chapter
4).

Proteomic and metabolomic mass informatics software were utilized to identify

proteins and metabolites in the MS/MS spectra. Statistical analysis revealed the proteins
and metabolites that were significantly different between exposed and control groups
(TiO2 rats) or cohorts (tau mice).

Significant proteins and metabolites were then input

into biopathway analysis software in order to elucidate the metabolic pathways that are
affected as a result of the exposure or treatment.
Protein bioinformatic software suites automate the analysis of MS and MS/MS
raw data by using various algorithms. For example, the Molecular Weight Search or the
MOWSE algorithm (later known as Mascot) [32] and the Sequest algorithm [33] were
developed in the early 1990’s as a means to identify proteins by using mass spectral
matching to the theoretical spectra. The Mascot approach uses a scoring process coupled
to a proprietary statistical analysis to provide a confidence limit for each spectral match
[32,34]. Sequest utilizes a cross correlation algorithm to deduce the quality of one match
[33,34]. These identification techniques became the basis of bottom up proteomics,
identification of proteins by mass spectral analysis of the proteolytically cleaved proteins
[35]. The advantage of bottom up proteomics is the ability to identify many different
proteins within a mixture and to achieve relative quantitation of the proteins [35]. A
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number of protein analysis software programs in use today employ one or both of the
above algorithms for protein identification. Protein analysis in this work was performed
with Proteome Discoverer (v. 1.4.0.288; Thermo Fisher, San Jose, CA) using the Sequest
algorithm, although the Mascot algorithm is also available for analysis in this program.
Metabolite bioinformatics software programs typically employ proprietary
algorithms for spectral identification based on exact mass matching or by fragment
matching [36]. Sieve (Thermo Fisher, San Jose, CA) identifies compounds by comparing
experimental MS exact mass information to exact masses within compound libraries.
Other programs such as Mass Frontier (Thermo Fisher, San Jose, CA), Compound
Discoverer (Thermo Fisher, San Jose, CA), XCMS Online (Scripps Research Institute, La
Jolla, CA), and Elements for Metabolomics (Proteome Software, Portland, OR) rely on
MS/MS data in addition to MS exact mass matches for compound identification. Sieve,
Mass Frontier, Compound Discoverer, XCMS Online, and Elements for Metabolomics
were utilized in this work for metabolite identification in Chapters 2, 3, and 4; however,
there was low confidence in the results. An analysis of these programs and others is
provided in Chapter 5.
Although LC-MS/MS is widely used for proteomic and metabolomic analyses,
LC requires minutes to hours for separation of proteins and metabolites and separation of
isomers and isobars by LC are challenging [19].

On the other hand, ion mobility

spectrometry (IMS) instrumentation is a gas-phase separation strategy that occurs on the
millisecond timescale and can be useful for separating isobars, isomers, and conformers
(as reviewed by reference [37]). Separation is achieved based on differences in ions’
collisional cross sections (CCS). Overall, ions that are more compact and more highly
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charged will traverse the mobility region faster than those ions that are more elongated
and have lower charge states [37,38]. These advantages of ion mobility are attractive for
the migration of bottom up proteomic and metabolomic analyses to an IMS-MS platform.
Gas-phase hydrogen/deuterium exchange (HDX) is an additional technique that
can be coupled with IMS-MS, and has been shown to be useful to study small molecules
[39–41] and to study protein structure and different conformations [42–46]. Gas-phase
HDX occurs through the introduction of a deuterium containing gas into the drift tube.
Ions react with the gas and the hydrogens on the protein or analyte of interest exchange
with the deuterium via a relay mechanism [47]. Hydrogens that are considered labile
(charged sites and heteroatom sites) will exchange. Those at charge sites will exchange
first, followed by other side chain heteroatoms, and then finally those on the amides of
the backbone [48]. The amount of deuterium incorporation and the resulting mass
spectral uptake pattern are dependent on the overall rate of exchange [49], which for
peptides and proteins depends on the primary amino acid sequence [50].
Hydrogen/deuterium (HD) scrambling occurs when added energy redistributes the
incorporated deuteriums to sites less accessible to HDX and hydrogens to sites more
accessible to HDX. The hydrogens relocated to more accessible sites can undergo HDX
resulting in further deuterium uptake. Like HDX, HD scrambling is highly dependent on
the ion characteristics [50–55], which may provide an additional parameter to identify
metabolites and proteins. In this work proof-of-principle analyses of the utilization IMSMS, HDX, and HD scrambling with HDX for rapid compound identification in the
absence of LC separation are presented in Chapter 6.
This work also provides future directions for the projects described in Chapters 2,
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3, 4, and 6. Future work includes multidimensional separation techniques, analysis of
post translational modifications (PTMs), isotopic labeling, and the development of new
instrumentation. Multidimensional separation techniques would be of interested because
of their ability to resolve proteins and metabolites that cannot be separated with the
reversed phased separation alone [56]. Analyzing for protein PTMs can offer additional
information about protein activation, inactivation, or other functions [57]. For example,
phosphorylation PTMs activate or inactivate proteins and ubiquitin PTMs can mark
proteins for degradation [57]. Isotopic labeling techniques afford a multiplex advantage
which reduces the error associated with run to run variability in ionization efficiency and
instrument performance and allows for a more accurate relative quantitation of proteins
[58]. Finally, new IMS instrumentation in development has the potential for great impact
on decreasing analysis times for complex mixture analysis following the strategy outlined
in Chapter 6.
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Chapter 2

Comparative plasma proteomic and metabolomic studies of
pulmonary TiO2 nanoparticle exposure in rats using liquid
chromatography tandem mass spectrometry
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2.1 Introduction
Over the last several years, the production of engineered nanomaterials (ENM)
has increased dramatically. Here, nanoparticles (NP) are defined as species exhibiting a
single dimension that is less than 100 nm in size. Such species find usage in a wide
variety of products ranging from electronic and cosmetic to medical and pharmaceutical
[1]. As an indication of their increasing usage, the number of consumer products sold in
the United States containing ENM as well as the work force involved in the production of
such products are expected to increase by more than an order of magnitude from 2008 to
2020 [2]. It has recently been estimated that to support this industry ~50,000 tons of
TiO2 nanoparticles alone are manufactured per year [3,4]. With this acceleration in NP
production comes a greater need to investigate the impact of increased exposure on
human health.
At the turn of the 21st century, investigative studies began associating air pollution
particulate matter exposure to cardiovascular events [5–9]. Since that time, significant
resources [10,11] have been dedicated to studies aimed at determining the effects of
particulate matter exposure on the cardiovascular system [12–14]. Concerned with the
limited applicability of macrovascular studies, a number of recent investigations have
focused on the effects of particle exposure on microvasculature function [15–25]. With
regard to NP exposure, such efforts have led to the development of three primary
hypotheses describing processes by which exposure affects microvascular function [26].
These include systemic inflammation and changes in autonomic influence.

A third

process involves direct tissue-NP contact resulting from particle translocation from the
lungs to the systemic microvasculature [26].
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These mechanistic hypotheses generate questions regarding the roles of various
molecular interactions in altering normal microvascular function.

A number of

experiments aimed at determining molecules associated with macrovascular dysfunction
indicate that particle exposure has been shown to elicit a systemic inflammatory
response.

For example, circulating levels of tumor necrosis factor (TNF alpha),

interleuken 1 (IL-1 beta), interleuken 6 (IL-6), endothelin 1 (ET-1), and c-reactive protein
(CRP) are observed to be elevated for human subjects after exposure to particles [27–29].
Analyses of bronchoalveolar lavage fluid (BALF) from animal studies have demonstrated
TiO2 NP exposure increases inflammatory cells, such as neutrophils and lympohcytes;
moreover, the observed increase of inflammatory cells was found to be dependent on
days after exposure [30–33], dose [32–34], and method of introduction (whole body
inhalation vs. intratracheal instillation) [33]. Gene expression analyses of lung tissue
have also shown immune and inflammatory responses as a result of TiO2 particle
exposure [34–36]

Furthermore, markers associated with oxidative and nitrosative

stresses in the microcirculation increase [20–22,25].
From such studies a better understanding that particle exposure with
microvascular dysfunction is emerging. Briefly, local inflammation in the lungs (resident
macrophages and epithelial cells) due to interaction with NPs results in recruitment and
activation of polymorphonuclear leukocytes (PMNs) [26].

Additionally, the local

response results in increased levels of cytokines and chemokines in the blood. The
circulating PMNs and cytokines result in the release of additional molecules associated
with inflammation, some of which may enhance leukocyte adhesion in the
microvasculature. Attachment of leukocytes to the vascular endothelium is believed to
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result in myeloperoxidase (MPO) deposition. Production of reactive oxygen species
(ROS) increases local oxidative stress [25]. This ultimately decreases bioavailable nitric
oxide (NO). Additionally, by-products of MPO-associated reactions result in decreased
endothelial NO production. The marked decrease in local NO levels results in impaired
arteriolar reactivity and further venular leukocyte adhesion.
Despite the success in determining relevant molecular responses (i.e., those
potentially affecting the microvasculature) resulting from particle exposure, many factors
remain to be elucidated. Currently the connection between pulmonary inflammation and
the downstream microvascular effects is not well understood [26]. For example, it is
unknown if secondary inflammatory markers released by activated PMNs (occurring at
the lungs) affect leukocyte adherence and reactive stress within the microvasculature.
Additionally, the role of secondary inflammatory markers in endothelial activation is not
well known.

Finally, the source of reactive stresses and their relationship to

inflammatory markers and vascular activation parameters is unclear.
The current study employs comparative proteomic and metabolomic analyses to
begin addressing the potential connections between pulmonary inflammation and
microvascular dysfunction from TiO2 NP exposure by examining protein dysregulation.
Proteomic and metabolomic studies were conducted using liquid chromatography with
tandem mass spectrometry (LC-MS/MS) under positive ion detection. Comparisons of
assigned protein and metabolite abundances between plasma samples obtained from rats
exposed to TiO2 NP's and a control cohort reveal a number of species that may be used to
distinguish sample types. These molecules have been used in biopathway analyses to
generate a molecular regulation network. The comparative proteomics, as well as the
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biopathway analyses, are discussed in light of recent findings associating NP exposure
and microvascular dysfunction.

2.2 Materials and Methods
2.2.1 Samples
Experimental animals. Male Sprague Dawley rats (175 - 250 g) were purchased
from Hilltop Laboratories (Scottdale, PA), and housed in laminar flow cages under
controlled temperature and humidity conditions and a 12 hr light/12 hr dark cycle at the
West Virginia University Health Sciences Center vivarium. Food and water were
provided ad libitum. All animals were acclimated for 72-hours before nanomaterial
inhalation exposure. To ensure that all methods were performed humanely and with
regard to alleviation of suffering, all procedures were approved by the Institutional
Animal Care and Use Committee of the West Virginia University.
ENM. Nano-titanium dioxide (TiO2) powder was obtained from Evonik
(Aeroxide TiO2, Parsippany, NJ). This ENM is a mixture composed of anatase (80%) and
rutile (20%) TiO2, with a primary particle size of 21 nm, and a surface area of 48.08 m 2/g
[24,37,38]. The nano-TiO2 was prepared for aerosolization by drying, sieving, and storing
the powder [19,24].
Inhalation Exposure. The Nanoparticle Aerosol Generator and exposure system
used for the current experiments have previously reported and described (U.S. Patent
#8,881,997) [19,24,39,40]. The system was developed specifically for rodent, wholebody nanoparticle inhalation exposures. Briefly, the apparatus was developed with a
vibrating fluidized bed, a Venturi vacuum pump, cyclone separator, impactor and mixing
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device, an animal housing chamber, and real-time monitoring devices. Aerosols were
generated by allowing a high velocity air stream to pass through the vibrating fluidized
bed and into the Venturi vacuum pump; drawing air and the TiO2 nanoparticles as it
passes. Aerosols enter the cyclone separator, which is gated to removed agglomerates
>400 nm at an input flow rate of 60 L/min of clean dry air before entering the exposure
chamber.
Size distribution, mean aerodynamic diameter, and relative mass concentration of
the aerosols were monitored in real time (Electrical Low Pressure Impactor (ELPI),
Dekati, Tempere, Finland). The particle size distribution was also measured in real-time
with a Scanning Mobility Particle Sizer device (SMPS; TSI Inc., St. Paul, MN). The realtime size distribution and mass concentration of the aerosols were monitored between 71000 nm with these devices. The count median aerodynamic diameter of the aerosols was
~160 nm. Once the steady-state aerosol concentration was achieved, exposure duration
was adjusted to achieve a calculated deposition of 30 µg/animal. Animals were exposed
for 4-6 hours per day for at a target mass concentration of 6.0 mg/m3 or to filtered air (0
mg/m3, control).
Blood collection and plasma isolation. 24 hours after ENM inhalation exposure,
rats were anesthetized by an intraperitoneal injection of thiobutabarbital sodium (100
mg/kg) and placed on a heating pad to maintain a rectal temperature of 37 ºC. The trachea
was intubated to ensure a patent airway, and the right carotid artery was cannulated to
measure arterial blood pressure and sample whole blood. Whole blood was collected via
the carotid artery cannula from live animals directly into Vacutainers containing K2
EDTA (BD Biosciences, San Jose, CA). Blood samples were immediately centrifuged for
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10 minutes at 2500 g. The plasma layer (supernatant) was then transferred into 1.5 mL
microcentrifuge tubes. These tubes were snap frozen in liquid nitrogen before being
placed at -80 ºC for long term storage.

2.2.2 Proteomics extraction and analysis procedures
Immunodepletion. A Seppro IgY14 immunodepletion kit was utilized (SigmaAldrich, St. Louis, MO) for immunodepletion of the 14 most abundant proteins in
plasma. Prior to depletion, 20 µL of plasma was diluted with 500 µL of 1

Dilution

buffer, added to a Corning Costar SpinX 0.45 µm column (Sigma-Aldrich, St. Louis,
MO), and centrifuged at 10000 g for 1 minute. 500 µL of the diluted plasma was
immunodepleted using Seppro IgY14 spin columns according to the manufacturer’s
protocol. Immunodepleted samples were frozen at -80 °C overnight and then dried down
in a vacuum concentrator at 35 °C for 8 hours. Samples were reconstituted in 1 mL of
200 mM ammonium bicarbonate with 6 M urea in water for further sample preparation.
Bradford Analysis. Total protein concentration of the immunodepleted samples
was determined using a Bradford Assay. Standards of bovine serum albumin (0, 0.25,
0.5, 0.75, 1.0, 1.5, and 2.0 µg/µL) were prepared and all samples and standards were
analyzed in duplicate. Protein concentrations were determined at 595 nm on an Epoch
Biotek UV-vis spectrophotometer (BioTek, U.S., Winooski, VT). The average sample
concentration was calculated and the amount of sample needed to react with 2 µL of 0.01
M dithiothreitol (DTT) at a concentration of 1:40 (protein:DTT) was determined.
Protein reduction, alkylation, and digestion. Plasma protein extractions were
prepared as outlined by Valentine, et al. with modifications [41]. The calculated aliquot
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of sample was diluted to a volume of 1 mL with 200 mM ammonium bicarbonate with 6
M urea. 2 µL 0.01M of DTT was added and the samples were incubated at 37 °C for 2
hours. Samples were placed on ice and 4 µL of 0.01 M iodoacetamide (IAM) was added.
Samples were incubated at 4 °C for 2 hours in the dark. 2 µL of 0.01 M cysteine was
added and samples were incubated at room temp for 30 minutes. 1 mL of 25 µg/mL
trypsin was added and samples were incubated at 37 °C for 18 hours. After trypsin
digestion, samples were stored at -80 °C overnight and then dried in a vacuum
concentrator for 8 hours at 35 °C. Samples were reconstituted in 150 µL sample buffer
(95/5 H2O/ACN + 0.5% TFA) and desalted using Pierce C18 Spin columns and
manufacturer’s protocol. After desalting, samples were dried at 35 °C and reconstituted
in 50/50 H2O/ACN with 0.1% formic acid for LC-MS/MS analysis.
Proteomic analysis by LC-MS/MS.

A Thermo Scientific Q Exactive mass

spectrometer with an Easy-nLC 1000 nano-LC was utilized (Thermo Fisher, San Jose,
CA). 18 µL of sample was injected onto a Thermo Scientific EASY-spray PepMap C18,
3 µm, 75 µm x 150 mm column (Thermo Fisher, San Jose, CA) with the column
temperature set to 35 °C. Mobile phases were A – H2O with 0.1% formic acid, and B –
ACN with 0.1% formic acid. At a flow rate of 20 µL/min, the sample gradient was as
follows: 40-minute linear gradient from 2% to 60% B; 20-minute linear gradient to 90%
B and hold for 10 minutes; 5-minute linear gradient back to initial conditions and hold for
5 minutes. MS settings were: positive mode; m/z range 150-2000; MS resolution 70,000
and automatic gain control (AGC) 1E6; data dependent MS/MS top 5 with S/N 5,
resolution of 140,000, AGC 1E5, normalized collision energy (NCE) 30, and isolation
window 4.0 m/z; spray voltage 1.80 kV; and S lens 60 V. Samples were analyzed in a
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random order.

2.2.3 Metabolomics extraction and analysis procedures
Sample preparation. A modified Bligh-Dyer extraction was used [42]. 750 µL
1:2 hexane:MeOH was added to 200 µL of plasma to precipitate proteins. An additional
250 µL of hexane was added along with 250 µL of water and mixed well. Samples were
centrifuged at 10000 rpm for 5 minutes at 4°C.

After centrifugation a layer of

precipitated proteins was observed between the layers and at the bottom of the tube. The
organic and aqueous fractions were carefully collected to avoid any collection of
precipitant. Fractions were dried down with a vacuum concentrator and reconstituted
with 50/50 H2O/ACN with 0.1% formic acid and then filtered through a nylon 0.2 µm
filter prior to LC-MS/MS analysis.
Metabolite analysis by LC-MS/MS. A Thermo Scientific Q Exactive mass
spectrometer with an Accela UHPLC was used (Thermo Fisher, San Jose, CA). 18 µL of
sample was injected onto a Phenomenex Synergi 4µ Fusion RP-80 2.0 x 100 mm column
(Phenomenex, Torrance, CA). Mobile phases were A – H2O with 0.1% formic acid, and
B – ACN with 0.1% formic acid. Using a flow rate of 200 µL/min, the sample gradient
was as follows: hold 2% B for 2 minutes; 60-minute linear gradient to 90% B and hold
for 15 minutes; 5-minute linear gradient back to initial conditions and hold for 10
minutes. MS settings: positive mode; scan type, MS/MS top 10 with S/N 5; resolution of
140,000; spray voltage 1.80 kV; capillary temperature 275°C, and S lens 60.

2.2.4 Informatics
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Proteomics.

Raw data files were analyzed with Proteome Discoverer (v.

1.4.0.288; Thermo Fisher, San Jose, CA) using the Sequest algorithm to search against
the rat.fasta database. Precursors were selected in a retention time window from 0 to 60
minutes with a mass range from 150 to 5000 Da. Charge states examined were +1 to +4.
The mass analyzer was set to FTMS, activation type to HCD, ionization source to
nanospray, and polarity to positive mode. The Sequest algorithm searched for peptides
ranging in length from 6 to 144 residues, allowing for 2 missed cleavages. A single
dynamic modification of carbamidomethyl was selected and the maximum modifications
per peptide was set at 3. Percolator confidence intervals were set at 0.05 and the decoy
database search was set at 0.1 for relaxed target and 0.05 for strict target. All other
default settings were used. Protein identifications are noted by their Uniprot Accession
identifier.
Protein comparisons based on the total number of high-confidence peptide ion
assignments were carried out using the Access Database software (Microsoft Office
2007, Microsoft Corporation, Redmond, WA). Additional abundance comparisons were
performed by first determining an abundance score based on the exponentially modified
protein abundance index (emPAI) technique described previously [43,44]. The emPAI
score (S) is computed as [44]
,

(1)

where Nobs is the total number of peptide ion assignments that are observed for a specified
protein and Nexp is the expected number of digest peptides from the protein sequence. For
these comparisons, Nexp is determined using the protein sequence length and the
frequency of occurrence of Lysine (~7.2%) and Arginine (~4.2%) amino acid residues
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[45]. The number of expected tryptic digest peptides for a given protein was estimated to
be the product of the sequence length and the sum of occurrence frequencies (expressed
as a decimal) of the two amino acid residues.
Differences in protein abundance were estimated based on comparisons of the
individual emPAI scores. The top 91 proteins in the highest abundance (at least 3 sample
hits) across all samples were chosen to supply the y-values (protein emPAI scores) for
principal component analysis (PCA) using the JMP Statistical software package (v.
11.2.0, SAS Institute Inc., Cary, NC) [46]. The PCA report includes a loadings matrix
value (LM), which demonstrates the degree of effect that a y-variable has on the principle
component. LMs range from 0 to 1, where values closer to 1 signify a greater influence
on the separation associated with a component. The LMs were then used to determine
proteins exhibiting the greatest degree of variation between the control and exposed
samples. The proteins that contributed the most (|LM| > 0.5) to the separation in principle
component 1 (PC1) were input into QIAGEN’s Ingenuity Pathway Analysis (IPA®,
QIAGEN Redwood City, www.qiagen.com/ingenuity) to determine molecular pathways
influenced by pulmonary nanoparticle exposure.
Metabolomics. Raw data files were analyzed with Sieve (v. 2.1.377; Thermo
Fisher, San Jose, CA).

Data files were aligned at a minimum intensity of 1000 and a

maximum retention time shift of 0.2 minutes. The data were framed by group (control
and exposed) with 5000 maximum frames and a retention time width of 2.5 minutes. m/z
values analyzed ranged from 75 to 1000 Da over retention times from 0 to 60 minutes.
Results were identified using the ChemSpider KEGG database with an m/z tolerance of
10.

Final Sieve results were screened to include only endogenous compounds as
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pharmaceuticals and phytochemicals identifications are inclined to be false positives.
Results from all samples were compiled and normalized for total metabolite content in
the sample. PCA of the normalized metabolite data was performed using JMP (v. 11.2.0,
SAS Institute Inc., Cary, NC) [46]. Similar to the proteomics data, metabolites that
contributed the most to the separation in PC1 (absolute value > 0.5) were input into IPA
(Qiagen, Hilden, Germany).
Biopathway Analysis. Biological pathways associated with the differentially
expressed proteins and metabolites were generated using the Ingenuity Pathway Analysis.
The biological pathways were obtained from a molecular input list comprised of those
proteins and metabolites exhibiting the greatest ability to distinguish the two sample
types based on PCA. For each protein and metabolite, the fold difference between the
average normalized emPAI score (protein) or peak intensity (metabolite) of the exposed
samples to the average normalized emPAI score (protein) or peak intensity (metabolite)
of the control samples was also input into IPA in order to determine up or down
regulation of pathways (see Table 2.1 for proteins and Table 2.2 for metabolites). To
generate the biological pathways, the core analysis function in the Ingenuity software was
performed on the input molecules. The Ingenuity Knowledge Base was used as the
reference set for analysis considering direct and indirect relationships. Molecules and
relationships were restricted to rat or undefined species. The number of molecules in
networks was restricted to 70 with 10 maximum networks. The top 3 canonical pathways
that were found to be most significant based on a calculated p score have been selected
for discussion (see section 2.3.4 Biopathway analysis).
It should be noted that there are limitations associated with using biopathway
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Table 2.1 – Protein inputs for Ingenuity Pathway Analysis
Accession
P55159
P31211
P04937-4
G3V8D4
P08934-2
P09006
P14480
P20059
P14046
P12346
E9PSV0
F1LR92
D3ZME7
P01048
D4A7D9
P04639
Q7TQ11
D4A6E3
Q5XIP6
G3V9J1
D3ZFC6
B2RYM3
P08932
F1LWK5
P02767
D3ZKV1
P02770
Q68FT8
Q68FP1-2

a

Description

b

Symbol

Serum paraoxonase/arylesterase
Corticosteriod-binding globulin
Isoform 4 of Fibronectin
Apolipoprotein C-II
Isoform LMW of Kiniogen-1
Serine protease inhibitor A3N
Fibrogen beta chain
Hemopexin
Alpha-1-inhibitor 3
Serotransferrin
Protein C4-2
Serine protease inhibitor A3M
HscB mitochondrial iron-sulfur cluster co-chaperone
T-kininogen 1
Anionic trypsin-2
Apolipoprotein A-1
Vitronectin
Murinoglobulin-1
Flap endonuclease 1
Protein LOC297568
Inter-alpha-trypsin inhibitor heavy chain family,
member 4
Inter-alpha trypsin inhibitor, heavy chain 1
T-kininogen 2
Protein Paqr9
Transthyretin
Monocarboxylate transporter 2
Serum albumin
Protein Serpinf2
Isoform 2 of Gelsolin

c

Fold
d
difference

PON1
SERPINA6
FN1
APOC2
KNG1
SERPINA3N
FGB
HPX
A1|3
TF
C4A/C4B
SERPINA3M
HSCB
MAP1
PRSS2
APOA1
VTN
MUG1
FEN1

*
*
-14.28
-6.63
*
-2.52
-1.54
1.47
-1.45
1.38
-4.62
-3.95
**
-2.17
*
1.56
-2.29
5.01
**
**

ITIH4

-2.69

ITIH1
KNG1/KNG1|1
PAQR9
TTR
Slc16a7
ALB
SERPINF2
GSN

-1.73
*
*
1.58
*
1.43
1.62
-3.10

Table 2.1 – List of proteins used as inputs for IPA as determined from PCA analysis (|LM| > 0.5 in
PC1). Where a – Uniprot protein Accession number, b – Uniprot protein name/description, c –
Uniprot protein symbol, and d – the ratio of the average emPAI score for the exposed samples to
the average emPAI score for control samples. * indicates the protein was not detected in the
exposed samples. ** indicates the protein was not detected in the control samples.
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Table 2.2 – Metabolite inputs for Ingenuity Pathway Analysis
CID

a

5280903
193429
19069
13711
997
5281128
445995
6057
6140
159623
1175
6443013
444899
5753
10917
6140
213144
5312830

Molecule

Fold
difference

b

Sphingosine 1-phosphate
Alpha-phocaecholic acid
Cyclic IMP
2'-Deoxycytidine
Phenylpyruvic acid
8-Hydroxylinoleic acid
Geranyl diphosphate
L-Tyrosine
Docosahexaenoate
3-Keto-lithocholic acid
Uric Acid
(13S)-Hydroxyoctadecadienoic acid
Arachidonic acid
Corticosterone
(-)-L-Carnitine
L-Phenylalanine
Butyrylcarnitine
(9S)-Hydroxyoctadecadienoic acid

1.47
-2.16
-2.36
1.67
1.66
-2.55
-1.85
1.64
1.69
1.72
1.72
-2.11
1.07
1.49
-1.13
1.10
-1.12
-1.10

Table 2.2 – List of metabolites used as inputs for IPA as determined from PCA analysis
(|LM| > 0.5 in PC1). Where a –PubChem CID number, b – PubChem molecule name, and
c – the fold difference of the average peak intensity for the exposed samples to the
average peak intensity for control samples.
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analysis software to determine relevant biological pathways based on differentially
expressed genes, and protein and small molecule abundance differences [47].

For

example, in using pathway topology software such as IPA, biopathways are dependent on
the type of cell and condition or disease state analyzed. The results are a snapshot of the
biological system at a given time point and are not able to fully characterize the dynamic
states of the system. Furthermore, the inter-dependence of pathways may not be realized
due to weak links between pathways [47]. Despite the limitations, the information gained
from biopathway analysis is useful as a starting point in understanding cause and effect
relationships resulting from biological stressors.

2.3 Results and Discussion
2.3.1 Identified proteins and peptides
All identified proteins and peptides were identified at the 95% confidence
interval. The LC-MS/MS analysis employed here resulted in identification of 367 total
proteins from all the samples; 260 proteins from control samples (n=7) and 207 proteins
from exposed samples (n=7). For a full description of the protein complement, see the
supplementary information “Chapter 2 protein data supplemental.” 8275 total peptides
were found in all the samples with 1361 unique peptides identified; 1114 and 881 unique
peptides were from control and exposed samples, respectively. Lengths of peptides
observed ranged from 6 to 47 for both the control and exposed samples. Peptide charge
states for the control samples have been identified as [M+4H]4+, [M+3H]3+, [M+2H]2+,
and [M+H]+, and comprise ~7.9%, ~36.9%, ~44.9%, and ~10.2%, respectively, of the
total peptide compliment. Similarly, the same peptide charge states for the exposed
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samples were found to be ~7.6%, ~39.2%, ~47.7%, and ~5.4%, respectively of the total
peptide compliment. Using the ratio of the total number of high confidence peptides to
the total number of strict target decoy database peptide hits yielded an actual false
discovery rate (FDR) of 3.8% [48].
367 total proteins were identified from all the samples; 78 proteins were identified
by at least 2 unique peptides. Control samples (n=7) had 260 total proteins and 72
proteins with at least 2 unique peptide hits, and exposed samples (n=7) had 207 total
proteins and 61 proteins with at least 2 unique peptide hits. In order to determine the
FDR of proteins, peptide hits were randomly removed equal to the number of false
positives (3.8% of 8275) [49]. The number of proteins identified by the number of
remaining peptides was divided by the number of total proteins identified and subtracted
from 100%. This resulted in and FDR of 2.3%. For a full description of the protein
complement, see the supplementary information “Appended emPAI scores” and “emPAI
scores from Access” tabs in “Chapter 2 protein data supplemental.”
The protein locations and functions were found using the QuickGO browser [50].
The 367 identified proteins represent 195 unique locations within the cell of 833 total
locations identified. The top 19 protein locations totaling 500 hits and their location
counts are shown in Figure 2.1A. 319 unique protein functions were identified from a
total of 833 functions. The top 18 functions totaling 308 hits and their individual function
counts are shown in Figure 2.1B. For a complete list of the locations and functions see
supplemental material “Protein locations” and “Protein biofunctions” tabs in “Chapter 2
protein data supplemental.”
The dynamic range of proteins in rat plasma is similar to that of humans,
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approximately 9 orders of magnitude [51]. Immunodepletion columns are commonly
used to remove a large portion of the most abundant proteins within plasma; for example,
albumin and IgG are reported to comprise 80-85% of the total plasma protein. The
immunodepletion process does not completely deplete the targeted compounds; in our
analysis albumin was still found to comprise a significant fraction of the protein content.
Even after immunodepletion the dynamic range of the serum proteins is still several
orders of magnitude; however, the detection of mid and low abundant compounds is
improved [51].

2.3.2 Protein comparison
emPAI scores were calculated (see equation 1 in Methods: Informatics above) for
each identified protein in each sample. The resulting scores and associated proteins were
input into a database (Microsoft Access) for query analysis. The compiled emPAI scores
for each protein were normalized to the total emPAI value for each sample. Proteins that
had 3 or more sample hits were selected to be used for inputs for PCA. Proteins with 2 or
fewer samples hits were considered to be indeterminate because they were found in only
less than 15% of the samples, whereas proteins with 3 or more sample hits are found in
approximately 20% of the samples. See supplementary information for emPAI scores
used for PCA inputs on the “Selection of proteins” tab in “Chapter 2 protein data
supplemental.” As a result of this filtering, a total of 58 proteins were selected to be used
as inputs for PCA (“JMP import” tab supplementary material) and IPA (“IPA input” tab
supplementary material) in “Chapter 2 protein data supplemental.”
The PCA of proteins shows a separation of the control and exposed samples
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primarily along principal component 2 (PC2, Figure 2.2). Additionally, a smaller
deviation is observed along PC1 where the majority of the exposed and control samples
are observed to exhibit positive and negative PC1 values, respectively. One exposed
sample is shown to have clustered with the control samples; however, the sample was not
excluded because the emPAI scores for 43 out of 58 proteins (74.1%) were within 1
standard deviation of the mean exposed emPAI score. Another exposed sample appears
to be an outlier, but it was not excluded because the emPAI scores for 57 out of 58
proteins (98.3%) were within 1 standard deviation of the mean exposed emPAI score. 38
proteins were shown to contribute to the separation in PC1 and PC2 at LMV values > 0.8
and subsequently, these proteins were used as inputs for IPA. Table 2.1 shows the top 20
protein inputs based on the highest summed emPAI scores. Complete loadings matrix
values of PC1 and PC2 and the calculated loadings matrix vector can be found in
supplementary information on the “JMP loadings results” tab in “Chapter 2 protein data
supplemental.”
A student’s t test was also performed on the emPAI scores for the 58 proteins (see
supplementary information “JMP import” tab in “Chapter 2 protein data supplemental”).
7 proteins were found to be significantly different (p ≤ 0.05); 6 of these 7 proteins were
found to be significant in the separation of the groups by PCA. The 7 significant proteins
are: inter-alpha trypsin inhibitor, heavy chain 1 (accession B2RYM3), protein Itih4
(accession D3ZFC6), apolipoprotein A-I (accession P04639), alpha-2-macroglobulin
(accession P06238), serine protease inhibitor A3N (accession P09006), serotransferrin
(accession P12346), hemopexin (accession P20059).

The 7 proteins and their fold

differences were used separately as inputs for IPA (see supplementary information “IPA
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import significant proteins” tab in “Chapter 2 protein data supplemental”). The resulting
biopathway analysis revealed the same top 3 canonical pathways as being significant (p ≤
0.05) as with the 38 proteins from PCA. There were differences in the z scores compared
to the IPA of 38 proteins, but none were considered to be significantly up or down
regulated (see supplementary information “IPA output significant proteins” tab in
“Chapter 2 protein data supplemental”). The IPA results from the 38 protein inputs
represent a more in depth analysis and the remainder of this manuscript will focus on the
results for the 38 proteins.

2.3.3 Metabolite comparison
524 unique mass peaks were found in the aqueous fraction.

124 aqueous

metabolites were identified by ChemSpider KEGG search and are listed by their
PubChem CID number on the “Aqueous Peak IDs” tab in “Chapter 2 metabolite data
supplemental.” 299 unique mass peaks were found in the organic fraction. 70 organic
metabolites were identified with a ChemSpider KEGG search and are listed on the
“Organic Peak IDs” tab in “Chapter 2 metabolite data supplemental.” All identified
metabolites were found in both the control (n=5) and exposed (n=6) sample groups. After
screening identified metabolites for endogenous mammalian compounds and duplicate
compounds, a total of 19 compounds from the aqueous fraction and 4 compounds from
the organic fraction were identified. The metabolites and their intensities were used as
inputs for PCA. 47% of the variation of the data points can be explained by PC1 (Figure
2.3). The 18 metabolites that contributed the most to the separation in PC1 at an absolute
value of ≥ 0.5, and were used for IPA (Table 2.2). The top 6 metabolites (absolute value
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≥ 0.83) were identified as: sphingosine 1-phosphate (CID 5280903); alpha-phocaecholic
acid (CID 193429); cyclic IMP (CID 19069); 2'- deoxycytidine (CID 13711),
phenylpyruvic acid (CID 997), and 8-hydroxylinoleic acid (CID 5281128). A complete
list of the identified metabolites and their PCA loadings scores can be found in the
supplementary information on the “PCA loadings matrix” tab in “Chapter 2 metabolite
data supplemental.”

2.3.4 Biopathway analysis
In order to better understand the molecular differences between the two sample
groups, a biopathway analysis (see Section 2.2.4, Methods: Informatics above) has been
conducted using molecular inputs obtained from the proteomics and metabolomics data.
Proteins exhibiting weighted (see section 2.3.2 Protein comparison above) |LM| values
>0.5 from the PCA (29 proteins) were combined with the metabolites exhibiting |LM|
PC1 values >0.5 from the PCA (18 molecules) and input into IPA to search for
interactions with the Ingenuity Knowledge Base molecules. IPA created a network based
on the input proteins; metabolites are not considered in the networks, but are used to
determine canonical pathways. Input proteins that were found to interact with database
proteins were deemed network eligible and a network was generated such that the
interactions of the network eligible proteins were maximized. The network was given a
score based on the probability of observing the network by chance.

The network

generated by IPA as determined by the 29 protein and 18 metabolite inputs was given a
score of 39. The network is shown in Figure 2.4 and a list of the network molecules and
their relationships can be found in supplemental material in “Chapter 2 Cytoscape
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network.”
17 input molecules were found in the network (Figure 2.4), comprising of
approximately 1/4 of the molecules in the network. Of the 17 input molecules, 7 are up
regulated and 10 are down regulated. The network was characterized by Cytoscape [52].
There are 72 nodes with no isolated nodes, 36 multi-edge node pairs, and 59 self-loops.
The network diameter, or the largest distance between two nodes is 8 and the network
radius, or the minimum non-zero eccentricities of the nodes is 1. The characteristic path
length, or the average shortest path length is 2.994 and the number of nearest neighbors is
5.056. The number of connected components is 2, indicating strong connectivity; 27 of
the 63 molecules in the network (~43%) have 4 or more connections. The network hubs
are IL6, FN1, and Insulin.

IPA functional analysis of this network found the top

functions associated to be free radical scavenging, cell movement, and cardiovascular
system development and function, organismal development. Canonical pathways were
generated based on the 47 input proteins and metabolites. The most significant pathways,
those with p values <0.05, are found in Figure 2.5. A z score for the pathway is
determined from the predicted up or down regulation of a molecule. Those that are
predicted to be up regulated are given a +1 (N+) and those that are predicted to be down
regulated are given a -1 (N-). The N+ and N- are summed to give N. The z score is then
calculated by equation 2 [53]:
,

(2)

where a z score of ≥ |2| is considered significant. Biopathway analysis of the 47 proteins
and metabolites indicated 1 canonical pathway (acute phase response signaling) to have a
negative z score, or is down regulated, but not significantly.
38
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The top 3 canonical pathways based on p value were found to be acute phase
response signaling, liver x receptor/retinoid X receptor (LXR/RXR) activation, and
farnesoid X receptor/retinoid x receptor (FXR/RXR) activation. Biopathway analysis
implicated the top 3 biological functions based on the p value as synthesis of reactive
oxygen species, activation of cells, and vasculogensis. Synthesis of reactive oxygen
species and vasculogensis had negative z scores (down-regulated) and activation of cells
had a positive z score (up-regulated). However, the associated z scores were not large
enough to be considered significantly up or down regulated, nor were any other
calculated z scores from the biological functions considered to be significantly up or
down regulated. The top toxicological functions based on p value were proximal renal
tubule toxicity, fibrosis of the heart, decreased synthesis of albumin, and fibrosis of the
left ventricle. There are no associated z scores with the toxicological functions. The
associated molecules, p-values, and z scores for each pathway and function mentioned
above are listed in Table 2.3. See supplementary information for complete bioanalysis
data in “Chapter 2 protein data supplemental.” We will focus the remainder of our
discussion on the canonical pathways found to be most significant from our 47 input
proteins and metabolites.
LXR/RXR activation plays a role in regulating lipid metabolism as well as the
catabolism of cholesterol to bile acids. FXR/RXR activation regulates many metabolic
processes including the regulation of bile, lipids, and glucose and is often complementary
and reciprocal to LXR/RXR activation. It is well known that changes in lipid and
glucose metabolism are associated with many diseases including type 2 diabetes, obesity,
and cardiovascular disease [54]. The p values of these pathways suggest that these
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Table 2.3 – Top statistically significant results from Ingenuity Pathway Analysis
Ingenuity Canonical
Pathways
Acute Phase
Response Signaling

P value

Z score

3.61E-19

-1.633

LXR/RXR Activation

1.41E-18

0.000

FXR/RXR Activation

2.69E-18

-

Biofunction Categories
Free Radical Scavenging
Cell-To-Cell Signaling and
Interaction
Cardiovascular System
Development and
Function, Organismal
Development
Tox Function Categories
Renal Damage, Renal
Tubule Injury
Cardiac Fibrosis
Decreased Levels of
Albumin
Cardiac Fibrosis

Diseases or
Functions
Synthesis of
Reactive
Oxygen Species
Activation of
Cells

Vasculogenesis

Molecules
ITIH4, C4A/C4B, FN1, TF, FGB, APOA1, SERPINF2,
SERPINA3, HPX, ALB, TTR
ITIH4, C4A/C4B, APOC2, TF, VTN, APOA1, SERPINF2,
HPX, ALB, TTR
ITIH4, C4A/C4B, APOC2, TF, VTN, APOA1, SERPINF2,
HPX, ALB, TTR
P value

Z score

Molecules

7.11E-09

-0.277

ALB, APOA1, APOC2, arachidonic acid, corticosterone, FN1, ITIH4,
KNG1, SERPINA3, TF, uric acid

4.31E-08

0.192

ALB, APOA1, arachidonic acid, C4A/C4B, FN1, KNG1, L-phenylalanine,
L-tyrosine, SERPINA1, SERPINF2, TF, TTR, uric acid, VTN

3.61E-07

Diseases or Functions

-0.239

P value

APOA1, arachidonic acid, corticosterone, FN1, Kng1/Kng1l1,
SERPINA3, Serpina3c/Serpina3m, TF
Molecules

Proximal Tubular Toxicity

1.87E-06

ALB, FGB,FN1,HPX, KNG1

Fibrosis of Heart
Decreased Synthesis of
Albumin
Fibrosis of Left Ventricle

3.00E-04

APOA1, corticosterone, FN1

9.98E-04

ALB

9.98E-04

APOA1

Table 2.3 - Top statistically significant canonical pathways, biological functions, and toxicological functions as determined from the 29 proteins and
18 metabolites input into Ingenuity Pathway Analysis.

pathways are significant in relation to TiO2 NP exposure; however, our data does not
indicate whether these pathways are significantly up or down regulated.
Other researchers have studied the effect of NP exposure on lipid and cholesterol
levels. Bourdon and coworkers exposed C57BL/6 mice to carbon NPs via intratracheal
instillation and analyzed the high density lipoprotein (HDL), low density lipoprotein
(LDL), and cholesterol levels at 1, 3, and 28 days post exposure [55]. They found a
significant decrease in plasma HDL at 3 and 28 days post exposure, an increase in plasma
LDL at 28 days post exposure, and a marginal increase in hepatic cholesterol at 28 days
post exposure.

Another research group investigated the effect of nickel hydroxide NP

via whole body inhalation exposure for 5 hours per day, 5 days per week for a duration of
1 week or 5 months on apoprotein E-deficient mice [56]. In the examination of plasma
LDL and cholesterol concentrations, there was found to be no significant difference
between exposed and control samples despite the marked increase in atherosclorosis.
Additionally, Hu and coworkers exposed apoprotein E-deficient mice to TiO2 NPs at 3
different exposure levels via intratracheal instillation for 6 weeks [57]. The plasma HDL
levels were decreased in the high exposure group compared to control and the plasma
organic lipid ratios were increased in the high and medium exposure groups relative to
the control. The medium and high exposure groups also showed a significant increase in
the progression of atherosclerosis.
Although it cannot be discounted that the aforementioned studies have differences
in the type of NP exposure and model organism used, these studies suggest that lipid and
cholesterol metabolism are affected as a result of NP exposure. The biopathway analysis
of our data indicated that the LXR/RXR activation and FXR/RXR activation pathways
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are significantly related to the proteins found to contribute to exposed and control sample
differences as elucidated by PCA. The results of the previous studies also suggest that
significant differences in these pathways at later time points relative to exposure may also
be observed. We plan to examine the metabolites, particularly lipids and cholesterols,
and proteins at multiple time points post exposure in order to determine if there is a
significant up or down regulation in the LXR/RXR activation and FXR/RXR activation
pathways as a result of TiO2 NP exposure.
LXR/RXR activation pathway also plays a role in the regulation of inflammation.
Acute phase response signaling pathway is a rapid inflammatory response that can be
initiated by tissue injury or trauma. It is interesting to note that there is a negative z score
(down regulation) associated with acute phase response signaling, but it is not considered
significant. Others have observed an up regulation of the acute phase response signaling
pathway in response to TiO2 NP exposure via gene expression analysis of mouse lung
tissue [35,36]. Husian and coworkers examined differentially expressed genes from
mouse lung tissue after intratracheal instillation of low, medium, and high concentrations
of TiO2 NPs at 1, 3, and 28 days post exposure. Biopathway analysis of the differentially
expressed genes revealed a significant up regulation in the acute phase response signaling
and LXR/RXR activation pathways at 1 day post exposure and at all doses [36]. In a
separate paper, Saber and coworkers examined the BALF for inflammatory cells in these
same mice. The increase in the inflammatory cells found in BALF correlated to an
increase in the up regulation of acute phase response signaling and LXR/RXR activation
pathways, except at the low dose concentration. The low dose exposure compared to the
control did not show a significant difference in the inflammatory cell concentration in
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BALF at any time point [32]; however, the genes associated with the inflammatory
response were found to be perturbed indicating that inflammatory signaling has been
initiated, but without a measurable change in the inflammatory cells [36]. Halappanavar
and coworkers also noted an up regulation of the acute phase response pathway as a
result of gene expression analysis of mouse lung tissue and an increase in inflammatory
cells in BALF as a result of whole body inhalation of TiO2 NPs [35]. While there are
noted differences in these studies and ours, such as the species used, amounts of TiO2
NPs exposure, and tissue examined, parallels can be drawn from these studies to our
results.

We hypothesize that while acute phase response signaling and LXR/RXR

activation pathways are observed to be highly associated with the input proteins from
plasma, a significant up regulation in these pathways should be observed in vasculature
and lung tissues. Future comparative proteomic studies of plasma, vasculature, and lung
tissue will be performed to test this hypothesis.
As with the previous studies noted time dependent changes in lipid and
cholesterol metabolism [55–57], it would be also prudent to examine different time points
post exposure to determine when, or if, a significant up regulation pathway(s) related to
the inflammatory response are observed in plasma. Demonstrated by the work of
Gustafsson and coworkers, the BALF inflammatory cell concentrations of TiO2 exposed
rats via intratracheal instillation were examined at 1, 2, 8, 16, 30, and 90 days post
exposure [30]. The authors demonstrated an increase in the inflammatory cells peaking
at approximately 16 days post exposure. This work suggests that although an analysis of
plasma in the present study demonstrated a non-significant down regulation of the acute
phase response at 24 hours post exposure, additional time points are needed in order to

44

observe changes in the regulation of the inflammatory response.

2.4 Conclusion
In order to determine the molecular pathways involved after pulmonary exposure
to TiO2 NPs, comparative proteomic and metabolomic analyses were performed. 29
proteins and 18 metabolites were identified as being able to distinguish between the two
sample cohorts. Ingenuity Pathway Analysis of the 29 proteins and 18 metabolites
indicated the significant pathways associated with these molecules to be acute phase
response signaling, LXR/RXR activation, and FXR/RXR activation. The acute phase
response signaling pathways was found to be down regulated, although not significantly.
The top 3 significant biological functions were synthesis of reactive oxygen species,
activation of cells, and vasculogensis.

Synthesis of reactive oxygen species and

vasculogensis biological functions were down regulated (negative z scores) and the
activation of cells biological function was up regulated (positive z score), but none of
these biological functions were significantly changed.
We have planned further studies to examine larger cohorts and perform
metabolomic and proteomic analyses of plasma, vascular, and lung tissue. Furthermore,
we will examine different amounts of NP exposure to examine the differences in
molecular response and will examine responses at time points from hours to days post
exposure to determine molecular response changes over time.
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3.1 Introduction
Since the turn of the 21st century, an increasing body of work has revealed that
pulmonary exposure to particulate matter from ambient air pollution produces adverse
cardiovascular effects [1–7]. Because engineered nanomaterial (ENM) aerosols share
similar, if not identical particle size distributions with ultrafine particulate matter, an
increasing concern exists to aerosolized EMN's or nanoparticles (NP) may produce
similar outcomes. NPs were once limited to occupational exposures; however, exposures
have become much more ubiquitous due to their use in sunscreens [8–10], cosmetics
[11–13], paints [14–17], in vivo drug delivery systems [18–21], and environmental
remediation solutions [22–24].
Several studies have examined the physiological translocation and distribution of
the TiO2 NPs after exposure. Rats were exposed to TiO2 aerosols for 1 hour and then the
distribution of particles within the lung tissues were examined at 1 hour and 24 hours
post exposure [25]. The researchers found that approximately 24% of the TiO2 NPs had
crossed the epithelium barrier of the lungs with no significant difference between the
time points. They further concluded that the NPs themselves could move between tissues
freely [25]. An earlier study by Ferin, et al. examined the pulmonary retention of TiO2
NPs and fine particles (FP) after single exposure to NPs or FPs or after repeated
exposures to NPs or FPs for 12 weeks [26]. The authors concluded that the particle size,
dose, and dose rate influenced the migration of particles to the interstitium with the NPs
being more likely to migrate [26].
The physical presence of NPs activates clearance mechanisms within the body
and has been shown to produce systemic inflammatory responses. TiO2 NP exposure in
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animals has previously been shown to increase neutrophils and lympohcytes in
bronchoalveolar lavage fluid (BALF) [27–31]. This increase was found to be dependent
on method of introduction (whole body inhalation vs. intratracheal instillation) [30], dose
[29–31], and post-exposure duration [27–30]. Gene expression analyses of animal lung
tissue have demonstrated TiO2 particle exposure stimulates immune and inflammatory
responses [31–33]. Further animal studies have also shown an increase in markers
associated with oxidative and nitrosative stresses in the microcirculation [34–37].
It has also been demonstrated that different tissues will exhibit a difference in
response to NPs at the same post-exposure time point.

Halappanavar, et al. examined

the gene expression changes in mouse liver and lung tissue following whole body
inhalation exposure to TiO2 particles [32]. The authors only found 11 genes in the liver
tissue showing differential expression between controlled and exposed cohorts;
furthermore, the fold change of these genes was found to be less than 1.6. Within the
lung tissue 353 genes were found to be differentially expressed and of these, 53
demonstrated fold changes greater than 1.5 [32]. Another study demonstrated genes
within the acute phase response signaling pathway had a more pronounced fold
difference in the lungs compared to the liver at 1, 3, and 28 days after exposure to carbon
black NPs [38]. Although these studies have demonstrated differential responses in
tissues, the heterogeneous effects of NP exposure on the microcirculation within
functionally different organs has yet to explored.
The current study employs comprehensive comparative proteomics and
metabolomics utilizing LC-MS/MS instrumentation in order to better understand the
effect of NP exposure on the response of different levels of arteriolar vasculature.
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Proteomic and metabolomics analyses were performed on plasma, aorta, and resistance
vascular tissues obtained from rats exposed to TiO2 NPs or filtered air (control).
Comparisons of assigned protein and metabolite abundances between sample and tissue
types reveal a number of species that may be useful in determining differences in tissue
response.

These molecules have been used in biopathway analyses to determine

biopathways that have been altered as a result of NP exposure.

The comparative

proteomics and metabolomics, in addition to biopathway analyses, are discussed in light
of recent findings associating NP exposure and microvascular dysfunction.

3.2 Materials and Methods
3.2.1 Samples
Experimental animals. Male Sprague Dawley rats (175 - 250 g) were purchased
from Hilltop Laboratories (Scottdale, PA). The animals were housed in laminar flow
cages under controlled temperature and humidity conditions and a 12 hr light/12 hr dark
cycle at the West Virginia University Health Sciences Center vivarium. Food and water
were provided ad libitum. Animals were acclimated for 72-hours prior to nanomaterial
inhalation exposure. All procedures were approved by the Institutional Animal Care and
Use Committee of the West Virginia University (Animal Welfare Assurance Number
A3597-01).
Nanoparticles. Nano-titanium dioxide (TiO2) powder was purchased from
Evonik (Aeroxide TiO2, Parsippany, NJ). This mixture is composed of anatase (80%) and
rutile (20%) TiO2, with a primary particle size of 21 nm, and a surface area of 48.08 m2/g
[39–41]. The nano-TiO2 was prepared for aerosolization by drying, sieving, and storing
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the powder [39,42].
Inhalation Exposure. The NP aerosol generator and exposure system utilized
here has previously been described elsewhere (U.S. Patent #8,881,997) [39,42–44].
Briefly, the apparatus was developed with a vibrating fluidized bed, a Venturi vacuum
pump, cyclone separator, impactor and mixing device, an animal housing chamber, and
real-time monitoring devices. Aerosols were generated by allowing a high velocity air
stream to pass through the vibrating fluidized bed and into the Venturi vacuum pump;
drawing air and the TiO2 nanoparticles as it passes. Aerosols enter the cyclone separator,
which is gated to remove agglomerates >400 nm at an input flow rate of 60 L/min of
clean dry air before entering the exposure chamber.
The mean aerodynamic diameter, size distribution, and relative mass
concentration of the aerosols were monitored in real time (Electrical Low Pressure
Impactor (ELPI), Dekati, Tempere, Finland). The particle size distribution was measured
in real-time with a Scanning Mobility Particle Sizer device (SMPS; TSI Inc., St. Paul,
MN). These devices allow for monitoring of the real-time size distribution and mass
concentration between a range of 7nm - 10μm. The median aerodynamic diameter of the
aerosols was approximately 160 nm. Once the steady-state aerosol concentration was
achieved, the duration of the exposure was adjusted to achieve a calculated pulmonary
deposition of 30 µg/animal. This resulted in exposure times of 4-6 hours per day for a
target mass concentration of 6.0 mg/m3 or filtered air (0 mg/m3, control).
Plasma and tissue isolation. Rats were anesthetized 24 hours post inhalation
exposure with an intraperitoneal injection of thiobutabarbital sodium (100 mg/kg). A
rectal temperature of 37 ºC was maintained by placing the animal on a heating pad and
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the trachea was intubated to ensure a clear airway. Whole blood was collected through a
cannula in the right carotid artery directly into Vacutainers containing potassium EDTA
(BD Biosciences, San Jose, CA). Blood samples were immediately centrifuged for 10
minutes at 2500 g and then the supernatant (plasma layer) was transferred into 1.5 mL
microcentrifuge tubes. Prior to vascular tissue collection, the hearts were removed from
the anesthetized rats, a quick and efficient means of euthanasia consistent with
recommendations of the Panel on Euthanasia of the American Veterinary Medical
Association. Tissue samples were then harvested and transferred into 1.5 mL
microcentrifuge tubes. Tubes for both plasma and vascular tissue were immediately flash
frozen in liquid nitrogen and then placed at -80 ºC for long term storage.

3.2.2 Proteomic and metabolomic extraction and analysis
Plasma immunodepletion. A Seppro IgY14 immunodepletion kit (SigmaAldrich, St. Louis, MO) was utilized to immunodeplete the 14 most abundant proteins in
plasma. 20 μL of plasma was first diluted with 500 μL of 1× Dilution buffer. The
diluted plasma was added to a Corning Costar Spin X 0.45 µm column (Sigma-Aldrich,
St. Louis, MO) and centrifuged at 10000 g for 1 minute. The filtrate was added to the
Seppro IgY14 spin columns and immunodepleted following the manufacturer’s protocol.
Immunodepleted samples were frozen overnight at -80 °C and then placed in a vacuum
concentrator at 35 °C for 8 hours. Dried immunodepleted samples were reconstituted in
1 mL of 200 mM ammonium bicarbonate with 6 M urea in water for protein digestion. A
total of 14 control samples and 15 exposed samples were used for plasma protein
analysis.
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Tissue preparation. 100 µL of 1× PBS buffer was added to each frozen tissue
sample and homogenized with a pestle. An additional 100 µL of 1× PBS buffer was used
to rinse the pestle. Tissue samples were further processed by sonication on ice for 10
minutes. 400 µL of acetonitrile was then added to precipitate the proteins. Samples were
vortexed well and then centrifuged at 1500 g and 4°C for 1 hour for protein and
metabolite separation. Supernatant was transferred to another tube for metabolomic
analyses (see below) and the precipitate was used for proteomic analysis. 1 mL of 200
mM ammonium bicarbonate with 6 M urea in water was added; samples were vortexed
well and sonicated in an ice bath for 10 minutes. Samples were centrifuged at 1500 g at
4°C for 15 minutes to separate the remaining tissue from the supernatant containing
proteins. A total of 13 control aorta samples, 11 exposed aorta samples, 15 control
vasculature samples, and 15 exposed vasculature samples were prepared for protein
analysis.
Bradford Analysis. The Bradford Assay was used to determine the total protein
concentration from aliquots the immunodepleted plasma samples and the tissue
extractions. All samples and BSA standards (0, 0.25, 0.5, 0.75, 1.0, 1.5, and 2.0 µg/µL)
were analyzed in duplicate. Protein concentrations were determined at 595 nm on an
Epoch Biotek UV-vis spectrophotometer (BioTek, U.S., Winooski, VT). The average
sample concentration from the 2 replicates was calculated and the amount of sample
extract required to react with 2 µL of 0.01 M DTT at a concentration of 1:40
(protein:DTT) was determined.
Protein reduction, alkylation, and digestion. Plasma and tissue protein
reduction, alkylation, and digestion were performed as previously described [45].
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Briefly, the calculated aliquot of sample was diluted to a volume of 1 mL with 200 mM
ammonium bicarbonate with 6 M urea. 2 µL of 0.01M DTT was added to reduce the
samples and incubated at 37 °C for 2 hours. The samples were placed on ice and 4 µL of
0.01 M iodoacetamide (IAM) was added for alkylation at 4 °C for 2 hours in the dark. 2
µL of 0.01 M cysteine was added to quench the alkylation reaction and samples remained
at room temp for 30 minutes. 0.5 mL of 50 µg/mL trypsin was added to digest the
proteins for 18 hours at 37 °C. Digested samples were removed from the incubator and
stored at -80 °C overnight. Samples were then dried down for 8 hours at 35 °C using a
vacuum concentrator. Sample residues were reconstituted with 150 µL of 5% in water
(v/v) with 0.5% (v/v) TFA and desalted with Pierce C18 Spin columns according to the
manufacturer’s protocol. Desalted samples were once again dried for 8 hours at 35 °C in
a vacuum concentrator and reconstituted in 50% ACN in water (v/v) with 0.1% (v/v)
formic acid for LC-MS/MS analysis.
Metabolite fractionation. 300 µL of hexane was added to the metabolite fraction
(supernatant from protein precipitation step above). Samples were vortexed well and
then centrifuged for 5 minutes at 1500 g. The top hexane layer was transferred to another
tube for analysis of the organic constituents, and the bottom layer retained the aqueous
constituents. The organic and aqueous fractions were dried down with a vacuum
concentrator and reconstituted with 50% ACN in water with 15 mM ammonium acetate
and then filtered through a nylon 0.2 µm filter prior to LC-MS/MS analysis.
Peptide and metabolite analysis by LC-MS/MS. A Thermo Scientific Accela
UHPLC coupled to a Thermo Scientific Q Exactive Orbitrap mass spectrometer (Thermo
Fisher, San Jose, CA) housed at the WVU BioNano Research Facility was used for LC-
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MS/MS proteomic analyses. 18 µL of sample was injected onto a Phenomenex Synergi
4u Fusion C18, 4 µm, 2.0 mm x 100 mm column (Phenomenex, Torrance, CA)
maintained at ambient temperature.
Proteomic gradient separations utilized water with 0.1% (v/v) formic acid as
mobile phase A and acetonitrile with 0.1% (v/v) formic acid as mobile phase B. The
gradient separation using a flow rate of 200 μL/min was as follows: initial 2% B; linear
gradient to 60% B over 40 minutes; linear gradient to 90% B over 20 minutes; and hold
for 10 minutes. MS settings were: positive mode; m/z range 150-2000; MS resolution
70,000 and automatic gain control (AGC) 1E6; data dependent MS/MS top 10 with signal
to noise ratio (S/N) 5, resolution of 17,500 and AGC 1E5, normalized collision energy
(NCE) 30, and isolation window 4.0 m/z; spray voltage 1.80 kV; capillary temperature
275°C; and S lens 60 V. Samples were analyzed in a random order.
Metabolite gradient separations used water with 15 mM ammonium acetate as
mobile phase A and acetonitrile with 15 mM ammonium acetate as mobile phase B. The
flow rates were 200 μL/min for organic and aqueous fraction analysis. For the organic
fractions the sample gradient was as follows: initial 50% B, hold for 2 minutes, followed
by a linear gradient over 25 minutes to 100% B, and hold for 2 minutes. For the aqueous
fractions the sample gradient started at 2% B, was held for 2 minutes, followed by a
linear gradient over 25 minutes to 50% B, and was held for 2 minutes. MS settings were
the same for both organic and aqueous fractions: positive and negative mode; m/z range
60-750; MS resolution 70,000 and AGC 3E6; data dependent MS/MS top 15 with S/N 5,
resolution of 17,500, AGC 1E5, NCE 30, and isolation window 4.0 m/z; spray voltage
3.80 kV; capillary temperature 320°C; and S lens 61 V. Samples were analyzed in a
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random order within their respective fraction.

3.2.3 Informatics
Proteomics.

Raw data files were analyzed with Proteome Discoverer (v.

1.4.0.288; Thermo Fisher, San Jose, CA) to search against the rat.fasta database.
Precursor masses ranging from 150 to 5000 Da were selected from a time range of 0 to
62 minutes. Charge states examined were [M+H]+ to [M+4H]4+ using the FTMS mass
analyzer, HCD activation, and nanospray ionization source. Peptide lengths ranging from
6 to 144 residues allowing for 2 missed trypsin cleavages were searched with the Sequest
algorithm. A dynamic carbamidomethyl modification with 3 modifications maximum per
peptide was used. Percolator confidence intervals were set at p ≤ 0.05 for aorta and
plasma samples and p ≤ 0.10 for vasculature samples (see section 3.3 Results and
Discussion for why this confidence level was used). Identified peptide spectra were
searched against the decoy database containing reversed protein sequences. A p ≤ 0.10
relaxed target and p ≤ 0.05 strict target were used. All other default identification
settings were used. Proteins here and in supplementary material are noted by their
Uniprot Accession identifier.
Excel Spreadsheet software (Microsoft Office 2007, Microsoft Corporation,
Redmond, WA) was utilized to compile proteins identified from Proteome Discoverer.
Protein abundance scores were determined using the exponentially modified protein
abundance index (emPAI) technique described previously [46]. The emPAI score (S) is
computed as [46]:
,
60

(1)

where Nobs is the total number of observed peptide ion assignments for a specified protein
and Nexp is the expected number of peptides from the protein sequence. For these
comparisons, Nexp is estimated using the product of the protein sequence length and sum
of the frequency of occurrence of trypsin cleavable amino acid residues, lysine (~7.2%)
and arginine (~4.2%) [47]. This emPAI score represents relative protein abundances in
statistical and biopathway analysis.
Proteins and their emPAI scores were compiled with Access Database software
(Microsoft Office 2007, Microsoft Corporation, Redmond, WA). The compiled proteins
were further narrowed by selecting for proteins identified by at least 2 unique peptides
and then those found in at least 5 samples. A student’s t test was performed using Excel
software (Microsoft Office 2007, Microsoft Corporation, Redmond, WA) to determine
which proteins were significantly different (p ≤ 0.1) between control and exposed
samples. Proteins that were found to be significantly different in relative abundance were
used as inputs for Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City,
www.qiagen.com/ingenuity) [48]. A more relaxed p value was used for the t test in order
to maximize the number of protein inputs into IPA.
Metabolomics. Raw data files were analyzed with Elements for Metabolomics
(v. 1.2.1 Proteome Software, Portland, OR). The mixed search mode was utilized to scan
[M + H]+ [M – H]-, and [M + NH3]+ ions with m/z of 50 to 750 Da in a retention time
window from 0 to 62 minutes. The parent ion tolerance was set at 20 ppm and the
fragment ion tolerance was set at 0.5 ppm. Libraries searched were NIST, LipidBlast,
and Human Metabolome Database. Putative assignments were made based on those
metabolites with an MS2 score greater than 0.7. Identified metabolites were further
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filtered by those that were found in at least 4 samples. A student’s t test was performed
to determine which metabolites were significantly different (p ≤ 0.1) between control and
exposed samples. Finally, metabolites were filtered further to exclude phytochemicals,
pharmaceuticals, and other non-endogenous compounds.

The metabolites were

combined with the proteins and input into IPA. As with the protein inputs, a more
relaxed p score was used in order to maximize the number of metabolite inputs for
biopathway analysis.
Biopathway Analysis. Biological pathways associated with the proteins and
metabolites exhibiting significant abundance differences were determined using IPA. The
biological pathways for each sample type were acquired from 30 input proteins and 0
metabolites for aorta samples, 21 input proteins and 2 metabolites for plasma samples,
and 23 input proteins and 0 metabolites for vasculature samples. The ratio of the average
normalized emPAI score of the exposed samples to the average normalized emPAI score
of the control samples was calculated to determine the protein fold difference for each
sample type. The fold difference for the metabolites was found in the same manner but
rather the averaged peak intensities were used. The fold differences for each protein and
metabolite were used in pathways analysis in order to determine if any pathways have
been up or down-regulated as a result of NP exposure. 10 proteins exhibiting the largest
fold difference for each tissue type and the 2 plasma metabolites are listed in Table 3.1.
For the full complement of data, see Chapter 3 protein and metabolite supplementary data
for all tissues.
The core analysis function in the Ingenuity software was used to generate
canonical pathways based on input proteins and metabolites. The Ingenuity Knowledge
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Table 3.1 – Top proteins and metabolites by tissue
Aorta Accession

Description

F1M6T5
P50137
P01026
D4AEB3
P63259
Q01129
A0A0G2JUH8
G3V7K3
B2RZC9
P04636
Plasma
Accession/ HMDB ID
D4ABJ9

Uncharacterized protein
Transketolase
Complement C3
Helicase senataxin
Actin
Decorin
Sorting nexin-13
Ceruloplasmin
Kielin/chordin-like protein
Malate dehydrogenase

Q63472
F1LS89
P04642
P14480
Q03626-2
Q5I0I1
P04276
D4AB56
F1LSD3
HMDB08097
HMDB01043

Fold
Difference
9.48
-5.11
4.86
4.61
-4.24
-4.05
-4.04
4.00
3.70
-3.16
Fold
Difference
6.62

Description
Acyl-CoA desaturase 4
Potassium voltage-gated channel subfamily
member 1
Ryanodine receptor 2
L-lactate dehydrogenase
Fibrinogen beta chain
Murinoglobulin-1
Serine/threonine-protein kinase RIO2
Vitamin D-binding protein
Uncharacterized protein
Integrin beta
PC(18:1(9Z)/14:0)
Arachidonic acid

H

6.42

5.96
-4.95
4.13
3.77
3.69
3.56
3.17
-3.03
-2.91
2.40
Fold
Vasculature Accession Description
Difference
D3ZEH1
Protocadherin Fat 4
-4.26
A0A0G2JYL5
Axonemal dynein heavy chain 2
-2.22
D4A2D3
E3 ubiquitin-protein ligase MYCBP2
2.12
P42335
Inositol-trisphosphate 3-kinase B
-1.89
F1LRU2
Axonemal dynein heavy chain 17
-1.77
F1M789
Myosin-13
-1.72
F1M6V1
Heterochromatin protein 1-binding protein
1.57
Q64612
Receptor-type tyrosine-protein phosphatase V
-1.55
Q6ED65-3
Echinoderm microtubule-associated protein
1.46
G3V9Y1
Myosin, heavy polypeptide 1
-1.43
Table 3.1 - Top 10 proteins for each tissue type exhibiting the greatest fold difference. The 2
metabolites that were found to be significantly different in plasma and their fold difference are
shown here.
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Base with both direct and indirect relationships was used as the analysis reference set.
Molecules and relationships were restricted to the rat species and the number of
molecules in networks was restricted to 35 with 25 maximum networks.

The top

significant canonical pathways based on a calculated p score have been selected for
discussion below.

3.3 Results and Discussion
Proteins. There were 51218 individual peptides identified in the aortic samples
(23003 in the exposed samples and 28214 in the control samples). Aortic peptides
ranged in length from 7 to 45 residues for the exposed samples and 7 to 34 residues for
the control samples.

The charge states of the aortic peptides were comprised of

approximately <1% [M+H]1+, 31% [M+2H]2+, 64% [M+3H]3+, and 5% [M+4H]4+ ions
for both exposed and control samples. There were 90824 individual peptides identified in
the plasma samples (49674 in the exposed samples and 41149 in the control samples).
Plasma peptides ranged in length from 6 to 47 residues for the exposed samples and 6 to
42 residues for the control samples. The charge states of the plasma peptides were
comprised of approximately <1% [M+H]1+, 80% [M+2H]2+, 39% [M+3H]3+, and 1%
[M+4H]4+ ions for exposed samples and <1% [M+H]1+, 72% [M+2H]2+, 28% [M+3H]3+,
and <1% [M+4H]4+ ions for control samples. At the p ≤ 0.05 level, there were 450
individual peptides identified in the vasculature samples (272 in exposed samples and
178 in control samples). When the confidence level was decreased to the p ≤ 0.1 level,
187936 individual vasculature peptides were identified (92446 in the exposed and 95490
in the control samples).

Due to this great increase in identification, analysis was
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continued at the p ≤ 0.1 for the vasculature peptides and proteins. Vasculature peptides
identified at the p ≤ 0.1 level ranged in length from 6 to 42 residues for the exposed
samples and 6 to 43 residues for the control samples.

The charge states of these

vasculature peptides were comprised of approximately 75% [M+H]1+, 18% [M+2H]2+,
7% [M+3H]3+, and >1% [M+4H]4+, with similar distributions for the exposed and control
samples.
A total of 3914 proteins were identified in aortic extracts (1650 in exposed and
2264 in control samples), corresponding to a total of 913 unique proteins (386 in exposed
and 527 in exposed samples). A total of 4668 proteins were identified in the plasma
extracts (2631 in exposed and 2037 in control samples), corresponding to a total of 1313
unique proteins (732 in exposed and 581 in exposed samples). At the p ≤ 0.05 level, a
total of 271 proteins were identified in the vasculature extracts (136 in the exposed
samples and 135 in the control samples). This corresponds to 107 unique total proteins
(65 in the exposed samples and 57 in the control samples). When the confidence level
was decreased to p ≤ 0.1, a total of 52538 proteins were identified in the vasculature
extracts (25176 in the exposed and 27362 in the control), corresponding to 2058 unique
proteins (922 in exposed and 1136 in control). It is unclear as to what caused the
significantly lower number of proteins identified at the at the p ≤ 0.05 level. For the
statistical and biopathway analysis, the complement found at the p ≤ 0.1 level was used.
The locations and functions of the identified proteins in all groups were found using the
Quick GO database (European Bioinformatics Institute, Hinxton, Cambridge, UK) [49].
The top 10 locations and functions for each sample type can be found in Table 3.2. The
full complement of location and function can be found in Chapter 3 protein
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Table 3.2 – Top protein locations and functions by tissue
Aorta Location
Membrane
Cytoplasm
Nucleus

Count
111
108
101

Plasma Location
Nucleus
Membrane
Cytoplasm
Integral
component of
membrane
Plasma membrane
Extracellular
region

Count
324
289
228

Integral component of
membrane

83

Plasma membrane

55

Cellular component

50

Extracellular exosome

46

Extracellular space

74

Nucleoplasm

38

Extracellular region
Extracellular space

34
31

Extracellular
exosome
Mitochondrion
Cellular

Aorta Function
Metal ion binding
Molecular function
ATP binding
Nucleotide binding

Count
81
55
46
40

Nucleic acid binding

186
157
131

Vasculature
Nucleus
Location
Membrane
Cytoplasm
Integral
component of
membrane
Plasma membrane
Extracellular
exosome
Cellular
component

Count
86
83
74
57
39
34
23

67

Intracellular

21

64
64

Nucleolus
Mitochondrion

19
17

component
Plasma Function
ATP binding
Metal ion binding
Protein binding
DNA binding

Count
112
103
90
84

Count
50
45
33
28

33

Molecular function

75

Zinc ion binding

33

62

Hydrolase activity

33

44

DNA binding

22

Protein binding

29

Nucleotide binding
Nucleic acid
binding
Hydrolase activity
Transferase
activity

Vasculature
Nucleotide binding
Function
ATP binding
Metal ion binding
Protein binding
Poly(A) RNA
binding
Zinc ion binding

Molecular function
Transferase
DNA binding
25
42
activity
Nucleic acid
Transferase activity
22
Zinc ion binding
40
binding
Table 3.2. Top 10 locations and functions for proteins in each tissue type.
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42

25
23

21
19
16

supplementary material for each tissue.
The Venn diagram in Figure 3.1 depicts the relationship of proteins within each
sample type from a total of 3001 identified proteins; 707 from aorta, 1045 from plasma,
and 1588 from vasculature. The Venn Diagram Generator from the Bioinformatics and
Evolutionary Genomics group at Ghent University (http://bioinformatics.psb.ugent.be/
webtools/Venn/) [50] was utilized to generate the diagram. A list of common and unique
proteins for each group and comparison can be found in Chapter 3 protein supplementary
material for each tissue. There were 13 proteins that were found in all 3 sample types;
IPA analysis of these proteins revealed the significant canonical pathways (p < 0.05) as
“sucrose degradation V (mammalian)” and “agrin interactions at neuromuscular
junction.” There were 130 proteins found to be shared between plasma and vasculature
sample types. IPA analysis of these proteins revealed “cell cycle control of chromosomal
replication” and “cell cycle: G2/M DNA damage checkpoint regulation” were found to be
the top significant canonical pathways. There were 72 proteins found to be similar
between aorta and vasculature samples. Among the top significant pathways were found
to be “adipogenesis pathway” and “tRNA charging.” Finally, there were 111 proteins
found in both plasma and aorta samples. The top 3 canonical pathways as found by IPA
analysis of these proteins were “FXR/RXR activation,” “LXR/RXR activation,” and
“acute phase response signaling.”
Metabolites. A total of 2242 metabolites were identified in the aqueous fraction
across all aorta samples, 531 of these metabolites (294 in exposed and 237 in control) had
MS2 scores.

The aorta organic fraction compliment contained a similar number of

identified metabolites, 2297, with 541 metabolites (295 exposed and 246 in control)
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having a MS2 score. The combined plasma samples contained a total 1965 metabolites in
the aqueous fraction with 470 metabolites (272 in exposed and 199 in control) with a
MS2 score. The plasma organic fraction contained 6634 total identified metabolites, and
825 metabolites (431 in exposed and 394 in control) with a MS2 score. The combined
small vasculature samples had 2147 metabolites identified in the aqueous fraction with
517 metabolites (272 from exposed and 245 from control) with MS2 scores. Finally, the
vasculature organic fraction compliment contained 2030 identified metabolites, with 480
metabolites (236 from exposed and 244 from control) given MS2 scores.
The Venn diagram in Figure 3.2 shows the relationship of the identified
metabolites in aorta, vasculature, and plasma. There were a total of 116 combined unique
aqueous and organic metabolites identified in aorta tissue, 180 combined unique aqueous
and organic metabolites identified in plasma, and 105 combined unique aqueous and
organic metabolites identified in vasculature. 99 metabolites were common to all three
tissue types, 10 were common between aorta and plasma, but none were common
between aorta and vasculature or plasma and vasculature. 6 unique metabolites were
found in the vasculature, 7 unique metabolites were found in the aorta, and there were 71
unique metabolites in the plasma.
Of the identified metabolites in all tissue types, disregarding those that did not
have MS2 scores and were identified as phytochemicals, pharmaceuticals, or other nonendogenous compounds, only 2 were found to be significantly different between control
and exposed samples. The low number of significantly different identified metabolites
could be due to the metabolite identification software. Using metabolite identification
software to identify metabolites in LC-MS/MS analyses is complicated due to matrix
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effects from LC mobile phases or sample solution, differences in fragmentation energies
between the library and experimental conditions, and isobaric and isomeric interferences
[51,52]. These interferences and the drawbacks to metabolite identification software are
discussed in greater detail in Chapter 5.
Biopathway results. Proteins and metabolites that were found to be significantly
different between exposed and control samples by a student’s t test for each tissue type
were input into IPA for biopathway analysis. IPA revealed similar results for the aorta
and plasma samples; however, different, yet related results for vasculature. Aorta and
plasma samples both have “acute phase response signaling,” “LXR/RXR activation,” and
“FXR/RXR activation” as being in the top 5 significant pathways. These pathways and
their associated –log(p value) can be found in Figure 3.3. The full list of significant
pathways and the associated p values can be found in Chapter 3 protein supplementary
material for aorta and plasma. These 3 pathways were found to be the top 3 pathways in
previous analysis of plasma [45].

“Acute phase response signaling” is a rapid

inflammatory response to injury or trauma [53]. “LXR/RXR activation” helps to regulate
inflammation in addition to regulating lipid metabolism and cholesterol catabolism [54].
“FXR/RXR activation” is complementary to “LXR/RXR activation” and works to
regulate bile, lipids, and glucose levels [55]. Dysregulations of the “acute phase response
signaling” and “LXR/RXR activation” pathways are expected as many researchers have
noted increased inflammatory markers as a result of NP exposure [32,33,56–59].
However, perhaps less expected are observed changes in pathways associated with lipid
and cholesterol metabolism.
Recent studies have demonstrated that nanoparticle exposure in rats significantly
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alters lipid levels [60,61]. In a 2015 study by Sulaiman, et al., rats orally exposed to
gold-silver nanoparticles were shown to have significant changes in serum lipid levels
relative to the control (p < 0.05); however, these changes did not correlate with dosage
[60]. For example, rats exposed to 10 mg/kg gold-silver nanoparticles had increased
levels of total cholesterol, triglycerides, glycerol, and LDL-C relative to the control
group. Conversely, rats exposed to 50 and 100 mg/kg of gold-silver nanoparticles had
decreased levels of total cholesterol, triglycerides, and glycerol relative to the control
group, but no significant difference in LDL-C levels.

Furthermore, there was no

significant difference found between control and 10 mg/kg gold-silver nanoparticle
exposed rats in HDL-C levels, but the 50 mg/kg gold-silver nanoparticle exposed rats
were significantly higher than the control cohort and the 100 mg/kg gold-silver
nanoparticle exposed rats were significantly lower than the control [60].
Recently, Adeyemi, et al., exposed rats (oral) to platinum nanoparticles and
similarly there were significant alterations (p < 0.05) in serum lipid levels that did not
correlate with dose [61]. In this study, all exposure levels had increased levels of total
cholesterol relative to control. However, the 10 mg/kg and 50 mg/kg platinum
nanoparticle exposed rats exhibited significantly increased levels of triglycerides and
glycerol and the 100 mg/kg exposed rats exhibited significantly decreased levels of
triglycerides and glycerol. Furthermore, there was no significant difference found in
HDL-C levels for 10 mg/kg exposed rats, but there was significant increase in HDL-C
levels for 50 mg/kg and 100 mg/kg exposed rats. For LDL-C levels, there was no
difference for the 100 mg/kg exposed rats, but there was a significant increase in the 10
mg/kg and 50 mg/kg exposed rats [61].
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These two recent studies further support the idea that NP exposure can alter the
“LXR/RXR activation” and “FXR/RXR activation” pathways, but these alterations
appear to be dose and nanoparticle type dependent [60,61]. As these pathways are related
to liver function (cholesterol and bile regulation), it is unclear if the nanoparticles
themselves are effecting liver function or if it is a cascading biological effect. This
present study and a previous study [45] did not indicate the “LXR/RXR activation” and
“FXR/RXR activation” pathways as being significantly up or down regulated. Because
at 24 hours post exposure significant alterations in these pathways are not detected, it
may be hypothesized that examining time points prior to or after 24 hours would present
significant alterations.
Biopathway analysis for the vascular tissue samples revealed the top 5 pathways
as “ILK signaling,” “methionine degradation of homocysteine,” “D-myo-inositol (1,3,4)trisphosphate

biosynthesis,”

“cysteine

biosynthesis

III,”

and

“1D-myo-inositol

hexakisphosphate biosynthesis II (mammalian).” This work will focus on the “ILK
signaling” pathway and the two inositol pathways. These three pathways and their
associated –log(p value) are shown in Figure 3.3. The full list of significant pathways and
the associated p values can be found in the “Chapter 3 Vasculature protein supplementary
material.” ILK signaling has been shown to regulate the transcription of cyclo-oxygenase
II (COX-2), an enzyme that when upregulated promotes production of prostaglandins
leading to inflammation [62]. Previous histological analyses has indicated that
prostaglandins contribute to the dysfunction and vasodilatory response to acetylcholine in
coronary arterioles [34]. The inositol biosynthesis pathways help to regulate calcium
stores and channels within the cells which are important as secondary messengers for
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signal transduction [63,64]. Other researchers have also noted changes in calcium
signaling due to TiO2 NP exposure [33,65].
In work performed by Sun, et al. an intratracheal instillation of TiO2 NPs for 90
consecutive days at different doses examined genes and proteins in lung tissue related to
inflammation [59].

The researchers found a dose dependent response for many

inflammatory markers including COX-2, nuclear factor-κB (NF-κB), and TNF-α, all of
which are in the “ILK signaling” pathway. Both the genes and proteins for COX-2, NFκB, and TNF-α were found to be significantly increased in relation to increased dose of
TiO2 NPs. Additionally, the researchers noted TiO2 NP exposure increased the
production of reactive oxygen species and lipid peroxidation resulting in activation of
inflammatory pathways [59]. Although the TiO2 NP exposure times and total amounts
differ drastically between the aforementioned study and the present study, TiO2 NPs
appear to elicit similar responses for acute and chronic exposures. Such findings suggest
that future studies on the long term effects of acute and chronic exposures would be
prudent.
Work performed by Husain, et al. examined the effect of low, medium, and high
doses of TiO2 NPs via intratracheal instillation at 1, 3, and 28 days post exposure on the
gene expression and subsequent biopathway analysis of lung tissue [33]. At 3 days after
exposure, the “ILK signaling” and “calcium signaling” pathways were found to be
significant in all exposures. Many of the down-regulated genes identified in the day 3
analysis are known to regulate calcium homeostasis and muscle contraction resulting in
changes in muscle contraction and ion concentration within the lungs. However, there
was little to no inflammation noted in the lung tissue at low and medium doses. The
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authors concluded that inflammation may not be the underlying cause of changes in ion
signaling, but rather the result of particle retention in the lungs [33].
Although the significant pathways found for vasculature in this study differ from
those found in plasma and aorta, there are similarities in the functions of these pathways.
“ILK signaling” could be considered a pre-inflammatory response, or a pathway that
might be activated prior to the acute phase response signaling pathway. In “ILK
signaling” COX-2 transcription is increased to promote prostaglandin production, which
in turn stimulates inflammation. Prostaglandin synthesis can also be controlled through
the “LXR/RXR activation” pathway regulation of NF-κB mediated transcription of COX2. Figure 3.4 demonstrates the similarities in the signaling cascades within these 2
pathways.

The “D-myo-inositol (1,3,4)-trisphosphate biosynthesis” and “1D-myo-

inositol hexakisphosphate biosynthesis II (mammalian)” pathways regulate calcium
stores required for certain signaling cascades to occur. For example, the PI3K signaling
cascade within the “acute phase response” pathway is dependent on calcium signaling for
proper function.

The differences observed in the significant pathways from the

vasculature compared to the significant pathways from plasma and aorta may be a result
of time-dependent tissue response due to the proximity of the tissue to the initial point of
exposure. Future work will examine vascular tissue more distal from the lungs and heart
in addition to the plasma, aorta, and vascular tissue close to the heart to determine if there
are other early response pathways involved.

3.4 Conclusion
There were observed differences in the significant pathways as determined by
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biopathway analysis of extracted proteins and metabolites from aorta, vasculature, and
plasma from rats exposed to TiO2 NPs. In aorta and plasma, the “acute phase response
signaling,” “LXR/RXR activation,” and “FXR/RXR activation” pathways were found to
be significant and are consistent with a previous analysis of plasma from TiO2 exposed
rats [45].

These pathways are related to inflammation and changes in lipid and

cholesterol metabolism. However, analysis of the resistance vasculature revealed “ILK
signaling,” “D-myo-inositol (1,3,4)-trisphosphate biosynthesis,” and “1D-myo-inositol
hexakisphosphate biosynthesis II (mammalian)” as being significant. These pathways are
associated with changes in inflammation through production of prostaglandins and
changes in calcium signaling and storage within the cells. Despite these outward
differences between the significant pathways observed in the vasculature compared to the
plasma and aorta, the observed pathways have similar functions. The differences may
result from temporal differences in response due to the proximity of the tissue to the
initial site of injury.
The differences in the significant pathways in the tissue types suggest the type of
response elicited results from not only the tissue distance to the initial site of NP
introduction, but also the difference in the structure and function of the tissue. This
response is expected to change over time and by tracking these changes throughout
different sections of the vascular tree, it may be able to discern the systemic effect of NP
exposure. Future studies will examine the effect over time and the responses of will
analyze structurally and functionally different sections of the vascular tree and additional
organs such as the liver, kidney, heart, brain, and nervous system.
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4.1 Introduction
Tauopathies are a group of neurodegenerative disorders associated with
pathological misfolding and aggregation of the tau proteins [1] and include diseases such
as Alzheimer’s (AD) and frontotemporal dementia (FTD). Although there are reported
mutations of tau that lead to neurodegenerative diseases, such as FTD [2] and Pick’s
disease [3], AD has not been reported to contain mutated forms of tau. Mouse models
used to study AD often rely on mutated forms of tau predominate in other tauopathies.
For example, the rTg(TauP301L)4510 mouse expresses a proline-to-leucine mutation at
the 301st amino acid residue (P301L) of tau typically found in FTD. In order to create a
more AD-like model, increased hippocampal and neocortal expression of P301L tau is
driven by a forebrain-specific calcium- and calmodulin-dependent protein kinase-II
promoter system [4]. These P301L mutated mice present with tau hyperphosphorylation,
neurofibrillary tangles, neuron loss, and memory impairment [4], all of which match taurelated changes observed in AD. However, this model is not phenotypically accurate as
tau mutations are not observed in AD. Even among individuals with FTD, only
approximately 10% of patients have a familial form of the disease associated with a
single gene mutation, such as the P301L mutation. Most cases of FTD are considered
sporadic, or not inherited. Thus, while transgenic models of familial AD and FTD are
useful, understanding how they differ from sporadic forms of these diseases is critical.
Recent studies have demonstrated early stages of AD and FTD are preceded or
accompanied by deficits in glucose utilization and energy metabolism [5–8].
Intracerebroventricular (ICV) infusions of streptozotocin (STZ) have been shown to
produce insulin-resistance and decreased glucose metabolism in the brain, as well as a
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number of other molecular and pathological changes that mimic AD and FTD, including
tau hyperphosphorylation [9].

However, the effects of ICV-STZ have only been

examined in rodents that have the rodent form, not the human form, of tau. Here, ICVSTZ administration has been explored as a means to initiate early metabolic changes
observed in the brain of mice expressing the human P301L tau mutation and the wildtype human tau in order to create a more phenotypically relevant mouse model of AD and
FTD. This work is interested in the changes within the brain proteome as a whole rather
than changes observed in tau protein as a result of the ICV-STZ administration.
Comparative bottom-up proteomic analyses of brain tissue were employed in
order to determine if ICV-STZ treatment in wild-type tau mice could be used an
alternative tauopathy model to one which relies on tau genetic mutations (P301L mice).
Brain hemispheres, minus the hippocampus, were analyzed to determine the proteins and
biopathways affected as a result of the genetic background and/or treatment. Proteomic
analyses were performed on high resolution LC-MS/MS instrumentation. Biopathway
analysis was performed using a pairwise approach to compare cohorts. Comparisons
between cohorts revealed the Protein Kinase A signaling pathway as being downregulated, although not significantly, in 4 of the 6 comparisons. Furthermore, the 14-3-3
Mediated Signaling pathway was the most significant pathway based on the input
proteins; however, it was not found to be up or down-regulated in any comparison. There
is evidence to support that ICV-STZ treatment has an effect on protein abundances and
signaling cascades within human tau mouse models.

4.2 Methods

87

4.2.1 Samples
Subjects and Treatments. Mouse tissues samples were generated through a
collaborative effort with the Reed lab in conjunction with other work. The generation of
rTg(TauP301L)4510 (hereafter called P301L) and rTg(TauWT)21221 (hereafter called
WT) mice has been described elsewhere [10]. The P301L, WT, and genetic control mice
used in this study had unrestricted access to food and water and were group housed in a
temperature- and humidity-controlled colony room with a 12-hour light/dark cycle. To
suppress human tau expression during development, dams were placed on doxycycline
water (40 ppm) 2 weeks prior to breeding, and experimental offspring continued
doxycycline until they were approximately 2.5 months of age. On the day of ICV-STZ
surgery, doxycycline water was replaced with regular water and transcription of human
tau was allowed to occur for approximately 4 months [11]. All experimental procedures
were approved by the West Virginia University Animal Care and Use Committee
(Animal Welfare Assurance Number A3597-01).
Surgery and ICV-STZ Administration. On the same day mice were removed
from doxycycline, mice received either a single, bilateral infusion of ICV-STZ (3 mg/kg;
2.5 µl/side, hereafter called STZ) dissolved in 0.05 M citrate buffer vehicle (pH 4.5) or
vehicle (hereafter called Veh) into the lateral ventricles (AP: -0.5 mm, ML: +/- 1.0 mm,
DV: -2.5 mm). Microinfusion (GenieTouch Syringe Pump, Kent Scientific, Connecticut,
USA) of STZ or Veh was performed with a 28-gauge injector attached to a 25 µl
Hamilton syringe at a steady rate of 1 µl/min for 2.50 min per side with an additional 5
min for diffusion.
Dissection. At 6 months of age, after 4 months of human tau expression, mice

88

were euthanized with carbon dioxide. The brain hemispheres were separated, the
hippocampus removed for other analyses, and the remaining hemispheres were
immediately frozen on dry ice, and stored in the freezer at -80 °C. Due to problems with
sample preparation and storage, we were only able to secure limited numbers of samples
for analysis: CT-STZ (n=4), CT-Veh (n=2), P301L-STZ (n=5), P301L-Veh (n=3); WTSTZ (n=5) and WT-Veh (n=6). CT-Veh samples were not used for statistical analysis
due to the small sample size.

4.2.2 Proteomics extraction and analysis procedures
Sample extraction. Brain tissue samples were manually homogenized with 100
µL of 1 PBS buffer and a pestle. The pestle was rinsed with an additional 100 µL of 1
PBS buffer and the samples were sonicated on ice for 10 minutes. Proteins were
precipitated with 400 µL of acetonitrile followed by vortexing and centrifugation for 1
hour at 1500 g and 4°C. Supernatant was used for metabolomic analysis described in
section 4.2.3, and the solids were used for proteomic analysis. 1 mL of 6 M urea with 200
mM ammonium bicarbonate in water was added to the solids. Samples were vortexed
and sonicated on ice for 10 minutes. Samples were centrifuged for 15 minutes at 1500 g
at 4°C. The Bradford assay was performed on an aliquot of the supernatant to determine
total protein content of the sample.
Bradford Analysis. 5 µL of sample and standards of bovine serum albumin
(BSA; 0, 0.25, 0.5, 0.75, 1.0, 1.5, and 2.0 µg/µL) were added to a 96 well plate in
duplicate. 245 µL of Bradford reagent was added to each well and allowed to react at
room temperature for 5 minutes. Protein concentrations were determined at 595 nm on an
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Epoch Biotek UV-vis spectrophotometer (BioTek, U.S. Winooski, VT). The average
sample concentration was calculated and the amount of sample extract required to react
with 2 µL of 0.01 M dithiothreitol (DTT) at a ratio of 1:40 (protein:DTT) was
determined.
Protein reduction, alkylation, and digestion. Protein extractions were prepared
as previously described [12]. Briefly, the sample aliquot was diluted to 1 mL with 200
mM ammonium bicarbonate with 6 M urea. Disulfide bonds were reduced by adding of
2 µL 0.01M of DTT and incubating at 37°C for 2 hours. Samples were removed from the
incubator and immediately placed on ice. Samples were alkylated by adding 4 µL of 0.01
M iodoacetamide (IAM) and incubating at 4°C for 2 hours in the dark. Excess IAM was
quenched with 2 µL of 0.01 M cysteine and incubated at room temp for 30 minutes.
Proteins were digested with 0.5 mL of 0.05 mg/mL trypsin and incubated at 37°C for 18
hours. Following trypsin digestion, the samples were stored at -80°C overnight. Samples
were then dried for 8 hours at 35°C in a vacuum concentrator.

Samples were

reconstituted in 150 µL sample buffer [5% (v/v) ACN with 0.5% (v/) TFA in water] and
desalted with Pierce C18 Spin columns following the manufacturer’s protocol. After
desalting, samples were dried at 35°C and reconstituted in 50% (v/v) ACN with 0.1%
(v/v) formic acid in water for LC-MS/MS analysis.
Proteomic analysis by LC-MS/MS.

A Thermo Scientific Accela UHPLC

coupled to a Thermo Scientific Q Exactive Orbitrap mass spectrometer (Thermo Fisher,
San Jose, CA) housed at the WVU BioNano Research Facility was used for LC-MS/MS
proteomic and metabolomic analyses. 18 µL of sample digest was injected onto a
Phenomenex Synergi 4u Fusion C18, 4 µm, 2.0 mm x 100 mm column (Phenomenex,
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Torrance, CA) at ambient temperature. UHPLC separations utilized water with 0.1%
(v/v) formic acid as mobile phase A and acetonitrile with 0.1% (v/v) formic acid as
mobile phase B. The gradient at a flow rate of 200 μL/min was: initial 2% B; linear
gradient to 60% B over 40 minutes; linear gradient to 90% B over 20 minutes; hold for
10 minutes. Column was re-equilibrated by returning the gradient 2% B over 5 minutes
and holding for 10 minutes. MS settings were: m/z range 150-2000; MS resolution
70,000 and automatic gain control (AGC) 1E6; and positive mode. The MS/MS settings
were: data dependent MS/MS of the top 10 peaks with S/N 5, resolution of 17,500 and
AGC 1E5, normalized collision energy (NCE) 30, and isolation window 4.0 m/z. The
spray voltage was set to 1.80 kV, capillary temperature set to 275°C and the S lens set to
60 V. Samples were analyzed in a random order.

4.2.3 Metabolomics extraction and analysis procedures
Metabolite fractionation. 300 µL of hexane was added to the supernatant from
section 4.2.2. Samples were vortexed well and centrifuged at 1500 g for 5 minutes. The
hexane layer was transferred to another tube (organic fraction). The organic and aqueous
fractions were dried down with a vacuum concentrator and reconstituted with 50% ACN
in water with 15 mM NH4OH. Extracts were filtered through a nylon 0.2 µm filter prior
to LC-MS/MS analysis.
Metabolite analysis by LC-MS/MS. 18 µL of sample was injected onto a
Phenomenex Synergi 4u Fusion C18, 4 µm, 2.0 mm x 100 mm column (Phenomenex,
Torrance, CA) with the column at ambient temperature and analyzed by a Thermo Q
Exactive Orbitrap. Metabolite gradient separations used water with 15 mM NH4OH as
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mobile phase A and acetonitrile with 15 mM NH4OH as mobile phase B. The flow rates
were 200 μL/min for organic and aqueous fraction analysis. For the organic fractions the
sample gradient was as follows: 50% B hold for 2 minutes followed by a linear gradient
over 25 minutes to 100% B and hold for 2 minutes. For the aqueous fractions the sample
gradient started at 2% B and was held for 2 minutes. This was followed by a linear
gradient over 25 minutes to 50% B and held for 2 minutes. MS settings were the same
for both organic and aqueous fractions: negative mode; m/z range 60-750; MS resolution
70,000 and AGC 3E6; data dependent MS/MS top 15 with S/N 5, resolution of 17,500,
AGC 1E5, NCE 30, and isolation window 4.0 m/z; spray voltage 3.80 kV; capillary
temperature 320°C; and S lens 61 V. Samples were analyzed in a random order within
their respective fraction.

4.2.4 Informatics
Proteomics. Proteome Discoverer (v. 1.4.0.288; Thermo Fisher, San Jose, CA)
was utilized to analyze raw proteomics data. Proteome Discoverer searched for peptides
in a retention time window ranging from 0 to 62 minutes with masses ranging from 150
to 5000 Da and charge states from [M+H]+ to [M+4H]4+. The mass analyzer settings
were FTMS with an electrospray ionization source, higher-energy collisional dissociation
(HCD) ion activation, in positive mode. Identified peptides were searched against the
mouse.fasta database. The Sequest algorithm searched for matching peptides with a
minimum of 6 and a maximum of 144 residues, allowing for 2 missed cleavages. A
carbamidomethyl fixed modification (from IAM capping) was selected for a maximum of
3 modifications per peptide. The Percolator algorithm was used to identify incorrect
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spectral identifications using a decoy database and confidence intervals at p ≤ 0.05.
Percolator attempts to match the experimentally identified peptide sequence against a
reversed protein database to determine the false discovery rate (FDR) of the peptides.
The decoy database search significance was set to p ≤ 0.1 for a relaxed target and p ≤
0.05 for a strict target. All other default settings were used.
Approximate protein abundance scores were calculated using the exponentially
modified protein abundance index (emPAI) [13]. The emPAI score (S) is determined by
[13]:
,

(1)

where Nobs is the total ion assignments for an observed peptide of a specified protein and
Nexp is the expected number of peptides produced from a protein sequence. Nexp is
determined by multiplying total number of residues in a protein sequence by the
approximate abundance of lysine (~7.2%) and arginine (~4.2%) [14]. This emPAI score
is used here to approximate protein abundances for statistical and biopathway analysis.
Proteins identified by at least 2 unique peptides were compiled with Access
Database software (Microsoft Office 2007, Microsoft Corporation, Redmond, WA).
Proteins that were found in at least half of the samples were selected for statistical
analysis. One-way ANOVA and hierarchical clustering statistical analysis of all cohorts,
except for the CT-Veh cohort (see section 4.2.1), were performed using MetaboAnalyst
(v. 3.0, McGill University, www.metaboanalyst.ca) [15] by using the selected proteins
and their emPAI scores as inputs. The one-way ANOVA first identified the individual
proteins that were significant between the groups. Then, the top 50 proteins identified by
the one-way ANOVA were ranked by their calculated f and p values, indicating the
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degree of significance of the overall comparison, and then used to create the hierarchical
cluster. The cluster was generated with Euclidean distance to measure the similarity
parameter and Ward clustering to minimize the sum of the squares between two clusters.
The top 50 proteins were additionally used as inputs for biopathway analysis.

All

proteins used here are identified by their Uniprot Accession number.
Metabolomics.

Raw data files were analyzed with XCMS Online (Scripps

Research Institute, xcmsonline.scripps.edu) using a custom parameter based on the
parameters in the UPLC/Orbitrap analysis, but only changing the polarity to negative
[16].

Putative assignments were made based on score and approximate compound

polarity. A standard mixture of selected polar analytes was analyzed by LC-MS/MS in
order to confirm the identity of selected compounds (data not shown). Elution order of
organic compounds was based on work by Kroumova [17] and Peters [18]. Peak areas
were normalized with a normalization constant based on the protein concentrations as
determined by the Bradford analysis (Section 4.2.2). Normalized metabolite data was
then analyzed by MetaboAnalyst using hierarchical clustering. MetaboAnalyst did not
perform data imputation, filtering, or normalization prior to clustering. The heatmap was
generated with Euclidean distance and Ward clustering.

The top 25 metabolites

identified by ANOVA from the cluster analysis were used as inputs for IPA analysis.
Biopathway Analysis. Molecular regulation networks were generated using the
Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com) [19]. Data
was compared in a pairwise fashion; P301L STZ vs. P301L Veh; WT STZ vs WT Veh;
P301L STZ vs. CT STZ; WT STZ vs. CT STZ; P301L STZ vs WT STZ; and P301L Veh
vs. WT Veh. The regulation network was obtained from a molecular input list comprised
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of the top 50 proteins and top 25 metabolites identified by one-way ANOVA. The core
analysis function was used on the input molecules to generate the canonical pathways and
regulation networks.

Direct and indirect relationships were considered to generate

networks comprising of 35 molecules including endogenous chemicals. All data sources
and levels of confidence were considered in mouse brain tissues with all mutations. The
most statistically significant canonical pathway and one pathway with altered regulation
have been selected for discussion.

4.3 Results
Tau mice protein results. All identified proteins and peptides were analyzed at
the 95% confidence interval. The LC-MS/MS analysis employed here resulted in the
identification of 29218 total peptides. 3952 peptides (1125 unique) were identified in the
CT-STZ group, 2151 peptides (835 unique) in the CT-Veh group, 5765 peptides (1279
unique) in the P301L-STZ group, 4624 peptides (1241 unique) in the P301L-Veh group,
6559 peptides (1329 unique) in the WT-STZ group, and 6167 peptides (1401 unique) in
the WT-Veh group. The length of the peptides ranged from 6 to 42 (CT-STZ), 6 to 43
(CT-Veh, WT-STZ), 6 to 44 (P301L-STZ), and 6 to 47 (P301L-Veh, WT-Veh). Peptide
charge states for the total peptide complement for all samples has been identified as
[M+4H]4+, [M+3H]3+, [M+2H]2+, and [M+H]+, and comprise ~5.3%, ~31.1%, ~60.6%,
and ~3.0%, respectively, with similar distributions for each sample cohort. The ratio of
the total number of high confidence peptides to the total number of strict target decoy
database peptide hits yielded an actual false discovery rate (FDR) of 2.5% [20].
18485 total proteins were identified in all the samples which can be sorted into
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5258 unique proteins for all samples. 2353 of these were identified by at least 2 unique
peptides in all samples. CT-STZ (n=4) samples had a total of 773 proteins and 346
proteins (160 unique) were identified by at least 2 unique peptides. CT-Veh (n=2)
samples had a total of 379 proteins identified and 167 proteins (118 unique) identified by
at least 2 unique peptides. P301L-STZ (n=5) samples had a total of 1087 proteins
identified and 462 proteins (168 unique) were identified by at least 2 unique peptides.
P301L-Veh (n=3) samples had a total of 780 proteins identified at 360 proteins (176
unique) were identified by at least 2 unique peptides. WT-STZ (n=5) samples had 1115
proteins identified and 518 proteins (182 unique) were identified with at least 2 unique
peptide hits. WT-Veh (n=6) had 1124 proteins identified and 500 proteins (205 unique)
were identified with at least 2 unique peptide hits. In order to determine the FDR of
proteins, peptide hits were randomly removed equal to the number of false positives
(2.5% of 29218) [21]. The number of proteins identified by the number of remaining
peptides was divided by the number of total proteins identified and subtracted from
100%. This resulted in and FDR of 4.2%.
A symmetric Edwards-Venn diagram was generated using the InteractiVenn web
based tool [22]. Figure 4.1 shows the resulting diagram demonstrating the overlap of
proteins in each group. There were 95 proteins that were found in every group. CT-STZ
samples contained 11 unique proteins, no unique proteins in the CT-Veh cohort, 8 unique
proteins in the P301L-STZ samples, 11 unique proteins in P301L-Veh samples, 16
unique proteins in the WT-STZ samples, and 19 unique proteins in the WT-Veh samples.
“Chapter 4 protein supplemental” on the “Venn Diagram” tab contains lists of the
proteins that were within each group from the Edwards-Venn diagram generated with the
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Venn Diagram Generator from the Bioinformatics and Evolutionary Genomics group at
Ghent University (http://bioinformatics.psb.ugent.be/webtools/Venn/) [23]. The protein
locations and functions were found using the QuickGO browser [24]. The 1164 uniquely
identified proteins across all samples represent 452 distinctive locations within the cell of
3491 total locations identified. The top 20 protein locations totaling 1905 hits and their
location counts are shown in Figure 4.2a. 779 distinct protein functions were identified
from a total of 3220 functions. The top 20 functions totaling 1203 hits and their
individual function counts are shown in Figure 4.2b. For a complete list of the locations
and functions see the “Chapter 4 protein supplemental” data “Protein locations” and
“Protein functions” tabs.
Proteins identified by at least 2 unique peptides and found in at least half the
samples were used as inputs for hierarchical clustering analysis using MetaboAnalyst
[15]. A one-way ANOVA was used to calculate F and p values for all the input proteins
except from those in the CT-Veh cohort due to the small sample size. Proteins were
sorted based on their descending f values (increasing p values), and the top 50 were
selected as inputs for IPA. The biopathway analysis was performed in a group pairwise
fashion, as outlined above (see section 4.2.4). Figure 4.3 shows the dendrogram of the
top 50 proteins identified from the one-way ANOVA. The color represents the relative
emPAI scores for the proteins in each sample.
Tau mice metabolomics results. In the aqueous metabolite fraction, a total of
19178 MS/MS spectral features were identified, corresponding to 2670 possible
identifications across all retention times. In the organic fraction, a total of 16403 MS/MS
spectral features were identified, corresponding to 1656 possible identifications across all
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retention times.

Endogenous metabolites were only considered for potential peak

matches. Putative assignments were further refined by XCMS score and the polarity of
the compound. The organic compounds were additionally identified based on elution
order as determined by Kroumova [17] and Peters [18]. 52 aqueous compounds and 18
organic compounds were identified in this manner. 70 total metabolites were used for
hierarchical clustering inputs in MetaboAnalyst software and the top 25 metabolites were
identified by ANOVA. The cluster of metabolites can be found in Figure 4.4.
Biopathway results. IPA results showed 14-3-3 mediated signaling, phagosome
maturation, cell cycle G2/M DNA damage checkpoint regulation, and remodeling of
epithelial adherens junctions, and glycolysis I as being the top 5 significant pathways (p ≤
0.05) in all comparisons, except glycolysis I was not in the top 5 in the WT STZ vs CT
STZ comparison. There were no z-scores associated with these pathways, and thus it is
unknown if these pathways are up or down-regulated. IPA also determined the protein
kinase A signaling pathway to be significant (p ≤ 0.05) as well as calculated a z-score for
this pathway in all 6 comparisons. A z-score of -0.447 was calculated for both P301L
STZ vs. P301L Veh and WT STZ vs. WT Veh comparisons indicating that in the
respective STZ induced cohort the protein kinase A signaling pathway was downregulated compared to the respective Veh cohort. However, this z-score does not indicate
a significant down regulation (z is significant if z ≥ |2|).

Z-scores of -1.000 were

calculated for the P301L STZ vs. CT STZ and WT STZ vs. CT STZ comparisons, also
indicating a non- significant down regulation of the protein kinase A pathway in the
diseased group compared to the control. P301L Veh vs. WT Veh and P301L STZ vs.
WT STZ both had positive z-scores (0.447 and 1.342 respectively) indicating the
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pathway is up-regulated, but not significantly, in the P301L cohorts compared to the WT
cohorts. Table 4.1 lists the canonical pathways, the associated p value for each
comparison, and the input molecules relevant to the pathway.
A combined regulation network was created from the top network in all
comparisons (Figure 4.5) with the following related diseases and functions: cell death and
survival; neuronal disease; cell to cell signaling and interaction; and nervous system
development and function. 25 proteins were input into this network; 9 proteins were
increased on average in abundance in the comparisons and 16 proteins were decreased on
average in abundance in the comparisons. The combined network was analyzed using
Cytoscape [25]. There are 67 nodes, no isolated nodes, 42 multi-edge nodes, and 24 selfloops. The network diameter, or the largest distance between two nodes is 10 and the
network radius, or the minimum non-zero eccentricities of the nodes is 1. The
characteristic path length, or the average shortest path length is 3.238 and the number of
nearest neighbors is 7.373. The number of connected components is 1, indicating strong
connectivity; 32 of the 67 molecules in the network (47.8%) have 4 or more connections.
The network hubs are tumor protein p53 (TP53) and huntingtin protein (HTT) with 38
and 25 connections, respectively. HTT as a network hub in this analysis is not a surprise
as Huntingtin’s disease also involves tau dysregulation. The Cytoscape network can be
found in the “Chapter 4 Cytoscape network” supplementary material.

4.4 Discussion
Metabolite Dendrogram. Figure 4.4 shows the dendrogram of the metabolites
containing 2 main branches. The upper branch consists of non-polar compounds and the
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Table 4.1 Significant canonical pathways

Pathway

P301L STZ
vs.
P301L Veh

WT STZ
vs.
WT Veh

P301L
STZ vs.
CT STZ

WT STZ
vs.
CT STZ

P301L
Veh vs.
WT Veh

P301L
STZ vs.
WT STZ

14-3-3-Mediated Signaling

1.66E-07

1.66E-07

5.62E-08

5.62E-08

1.66E-07

1.66E-07

Phagosome Maturation

1.23E-05

1.23E-05

5.89E-06

5.89E-06

1.23E-05

1.23E-05

2.63E-04

2.63E-04

1.70E-04

1.70E-04

2.63E-04

2.63E-04

YWHAG,YWHAZ,YWHAB

7.76E-04

7.76E-04

5.01E-04

5.01E-04

7.76E-04

7.76E-04

TUBB4A,TUBB3,TUBA4A

1.29E-03

1.29E-03

4.68E-02

4.68E-02

1.29E-03

1.29E-03

GAPDH,GPI

4.27E-03

4.27E-03

1.38E-02

1.38E-02

4.27E-03

4.27E-03

YWHAG,GNB1,PPP3CA,YWHAZ,YWHAB

-0.447

-0.447

-1.000

-1.000

0.447

1.342

Cell Cycle: G2/M DNA Damage
Checkpoint Regulation
Remodeling of Epithelial
Adherens Junctions
Glycolysis I
Protein Kinase A Signaling - p
value
Protein Kinase A Signaling - Z
score

Molecules
TUBB4A,YWHAG,TUBB3,TUBA4A,
YWHAZ, YWHAB,GFAP
TUBB4A,PRDX6,TUBB3,TUBA4A,
ATP6V1E1

Table 4.1 – Above, the top 5 significant pathways as determined by Ingenuity Pathway Analysis, the associated p value for each comparison, and
the input molecules relevant to the pathway. Below, the p values and z scores for the only pathway to be identified as being up or down-regulated,
although not significantly, as determined by Ingenuity Pathway Analysis.
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lower branch consists of polar compounds.

MetaboAnalyst software is not able to

distinguish classes of compounds and creates the dendrograms only based on input
intensities.

It was serendipitous that the polar and non-polar metabolites grouped

together. The non-polar compounds tended to be higher in intensity in the CT-STZ
cohort, and the polar compounds tended to be higher in intensity in the P301L-STZ
cohort.
Significant Metabolites.

ANOVA analysis revealed 4 compounds as being

significantly different across the groups (p < 0.05, see Chapter 4 Metabolite
supplemental); myristic acid, pyroglutamic acid, isobutyric acid, and creatinine. Myristic
acid plays a role in cell signaling and membrane integrity. Pyroglutamic acid is found in
large amounts in the brain and is thought to be involved with a storage mechanism for
glutamic acid [26], but pyroglutamic acid also has negative implications in
neurodegenerative diseases such as Alzheimer’s [27]. Isobutyric acid is a short branched
chain fatty acid and is more often found in the gastrointestinal tract as a break down
product of gut metabolism. Creatinine is the break down product of creatine phosphate
from the muscle and shuttled to the blood to be metabolized in the kidneys for
elimination. Isobutyric acid and creatinine appear to be suspect identifications; however,
there was no alternate compound for creatinine identified and the alternate compound to
isobutyric acid was given as butyric acid. Because this work examines brain tissue,
creatinine may not be expected to be present in these samples as well as isobutyric acid.
Herein lies a major problem with untargeted metabolite identification.

Biologically

relevant compounds have been identified, but generally are not associated with the tissue
type examined in this study. The actual identities of these compounds may be the
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tentative assignments here, or not at all.
Although the metabolites were input into IPA with the identified proteins, few
pathways contained the metabolites as molecules of importance. Furthermore, in the top
5 identified pathways and the 1 pathway with a z-score no input metabolites were
identified as being relevant to the pathway.
Protein Dendrogram. The dendrogram in Figure 4.3 has 6 regions related by
similar relative protein intensity within various sample groups. The proteins within each
region were analyzed with IPA in order to determine the most likely pathway (as
determined by p value) that relates these proteins together. It should be noted that the
pathway, although related to the overall changes observed in the organism, is only the
most significant pathway for the small subset of proteins and not for the 50 input
proteins.
The top group (blue brackets) in the dendrogram consisting of 5 proteins showing
similar relative protein intensity in the P301L-STZ and P301L-Veh cohorts. The most
significant pathway for these proteins is the Glutamate Receptor Signaling pathway (p =
0.02). The second group (yellow-green brackets) comprised of 13 proteins is defined by
those proteins that are relatively more intense in the P301L-Veh and WT-STZ cohorts.
The nNOS (neuronal nitric oxide synthase) Signaling in Neurons pathway (p = 0.0007)
was found to be the most significant in this group. The third group (green brackets)
contains 5 proteins that have higher relative intensities in CT-STZ and WT-Veh cohorts.
These proteins showed the Glutathione Redox Reactions I pathway (p = 0.007) as being
the most significant. For the fourth group (brown brackets) which consists of 12 proteins
that are relatively more intense in CT-STZ and WT-STZ cohorts, the Glutamine
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Biosynthesis I pathway (p = 0.001) was determined to be the most significant. The fifth
group (orange brackets) contains 5 proteins that are relatively more intense in the WTSTZ cohort.

The most important pathway way is found to be Glutathione Redox

Reactions I pathway (p = 0.005). Finally, the sixth group (purple brackets) contains 10
proteins that are typically are more abundant in all cohorts. Hypusine Biosynthesis
pathway (p = 0.0006) was found to be the most significant pathway for this set of
proteins.
Significant proteins. Previous studies have demonstrated the expression of the
vesicular glutamate transporter 1 (vGLUT1, Accession Q3TXX4) is increased and the
expression of glutamate transporter 1 (GLT-1, Accession P43006) is decreased in P301L
mice relative to WT and control mice [10].

This present analysis did not identify

vGLUT-1 or GLT-1 proteins; however, the amino acid transporter, glial high affinity
glutamate transporter (SLC1A2, Accession A2APL7), was found mostly in the P301L
samples and only in one WT-Veh sample. SLC1A2 was determined to be in the top 50
proteins, but it not found to be significantly different in the one-way ANOVA (p ≥ 0.05).
Like the vGLUT and GLT-1 proteins, the SLC1A2 functions to transport glutamate
released from the cells across the plasma membranes and clear glutamate from the
extracellular space at the synapses. Low glutamate concentrations in the extracellular
fluid must be maintained, particularly in the synapse, in order to facilitate synaptic
transmission; moreover, high concentrations of extracellular glutamate is neurotoxic [28].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Accession P16858) was
found to be in the top 50 proteins in the one-way ANOVA, but GAPDH was not found to
be significantly different between any group (p≤ 0.05). GAPDH has a well-defined role
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in the glycolysis pathway; however, many recent studies have shown other functions
including regulation of gene expression, acting as a phosphotransferase, and interacting
with small molecules such as p53 and glutathione (as reviewed by reference [29]). More
relevant to this current body of work, GAPDH has also been shown to interact with
proteins associated with neurodegenerative diseases including Huntington's and
Alzheimer's (as reviewed by references [29,30]).
Another significant protein found by one-way ANOVA is glial fibrillary acidic
protein (GFAP, Accession P03995-2, p= 0.008). The Fisher’s LSD revealed that the
GFAP protein in the CT-STZ cohort was significantly different from P301L-STZ,
P301L-Veh, and WT-Veh cohorts, but not significantly different from WT-STZ cohort.
GFAP in the WT-STZ cohort was significantly different from the P301L-Veh and WTVeh groups, but not significantly different from the P301L-STZ cohort. GFAP has been
shown to anchor the glutamate/aspartate transporter (GLAST) and excitatory amino acid
transporter 1 (EAAC1) in the membrane [31]. GFAP was once thought to provide support
for astrocyte cells; however, an emerging body of work suggests GFAP plays a role in
regulation the blood brain barrier and signal transduction pathways (as reviewed by
reference [31]). Increased GFAP expression is known to occur with brain damage and
neuronal degeneration [31].

Dabir et al. demonstrated a regiospecific expression of

GFAP in P301L and WT mice with the protein being more highly expressed in the spinal
cord, followed by the brainstem, and the lowest expression in the cortex [32].
Furthermore, the expression of GFAP was found to increase in both the P301L and WT
mice compared to the controls.

This is in contrast to the significant decreases in

expression of GLT-1 and GLAST proteins in the spinal cord and brainstem [32]. GLAST
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and EAAC1 proteins were not identified in this present study, likely due to the data
dependent mass spectral analysis.
Significant pathways.

The Protein Kinase A Signaling Pathway utilizes

neurotransmitters and hormones to activate processes within the body related to growth,
memory, and metabolism [19].

Within this pathway protein kinase A (PKA)

phosphorylates glycogen synthase kinase-3 (GSK3) in order to inactivate GSK3 and
prevent phosphorylation of the tau protein and consequent neurodegeneration [19]. In
this present study, there was an observed down-regulation of this pathway in the P301L
STZ and WT STZ cohorts compared to CT STZ cohorts, as well as in the P301L STZ and
WT STZ cohorts with respect to the Veh control cohorts.

The Protein Kinase A

Signaling pathway was found to be up-regulated, but not significantly, as a result of the
STZ treatment in the P301L and WT cohorts. By inference it appears that the Protein
Kinase A Signaling Pathway is most down-regulated in the WT cohort, but also still
down-regulated in the P301L cohort compared to the controls.
14-3-3 Mediated Signaling was found to be the most significant pathway in all
comparisons. This pathway that utilizes 14-3-3 adapter and scaffold proteins to bind to
specific phosphoserine and phosphothreonine motifs in order to inhibit or activate
proteins, provide structural support, or to translocate other proteins [19]. Relevant to this
study, Li and coworkers examined the binding affinity of 14-3-3γ isomer (Accession
A8IP69) to GFAP as they are known to play protective roles in neurodegenerative
diseases [33]. GFAP was shown to associate with 14-3-3γ under phosphorylated and
hyperphosphorylated conditions, but no association was found under dephosphorylated
conditions [33]. Since 14-3-3γ was found in all of the samples and GFAP was found in
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70 percent of the samples, it is not unexpected that this was the most significant pathway
reported by biopathway analysis.

4.5 Conclusions
Comprehensive proteomics and metabolomic analyses were performed on genetic
control, P301L, and WT mice brains treated with ICV-STZ or a vehicle buffer control in
order to determine how the brain proteome and biological pathways are altered as a result
of the genetic background and STZ treatment. A one-way ANOVA of control, P301L,
and WT mice brains treated with ICV-STZ or a vehicle buffer control was used to select
the top 50 proteins and 25 metabolites by calculated F and p values. IPA analysis of
these proteins and metabolites revealed 49 of significant pathways across all comparisons
(p ≤ 0.05) and 1 of these pathways as being up or down-regulated (Protein Kinase A
signaling). There was an observed a down-regulation of this pathway, although not
significant, in 4 of the 6 comparisons. The Protein Kinase A signaling pathway regulates
various functions within the body including those related to memory as known inhibition
of this pathway contributes to cognitive decline. The 14-3-3 Mediated Signaling pathway
was found to be the most significant pathway based on the input proteins and metabolites;
however, it was not found to be up or down-regulated. This pathway has been found to
employ adapter and scaffold proteins in order to inhibit or activate proteins, provide
structural support, or to translocate other proteins. It also has been found to be key in
GFAP regulation.
There is evidence to support that ICV-STZ has an effect on protein and metabolite
levels and signaling cascades related to AD and FTD within the brains of P301L and WT
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tau mouse models used. In order to fully understand the effect of ICV-STZ treatment on
the human tau mouse models, additional studies are required to assess the effect of tau
pathology progression and cognitive function.
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Chapter 5

LC-MS/MS metabolomic analyses shortcomings
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5.1 – LC-MS/MS metabolomic analyses technique and hardware shortcomings
Metabolite compound identification can be performed with a variety of platforms
including: gas chromatography (GC); capillary electrophoresis (CE); nuclear magnetic
resonance (NMR); and liquid chromatography (LC). Each technique has its advantages
and disadvantages. GC works well for volatile compounds, but often compounds must be
derivatized prior to sample analysis to improve volatility or to add a functional group so a
compound may be detected with a particular detector [1]. GC - mass spectrometry (MS)
was once thought to be the gold standard for metabolite identification; however, it has
recently come into question for thermal degradation of compounds, leading to
misidentification of compounds [2].
CE provides the advantage of increased peak capacity and sensitivity over LC;
unfortunately, the low flow rates used in CE are challenging to couple to MS [3]. In
more recent years, improved interfaces have emerged to couple CE to mass spectrometers
such as the porous tip sheathless interface, the flow-through microvial interface, the
electro-osmotic flow driven sheath-liquid interface, and the porous emitter sheathless
interface [4]. As a result, CE has become a more popular technique for metabolite
identification particularly in the clinical metabolomics realm [4–8].
NMR spectroscopy has the advantage of allowing researchers to minimally
process samples prior to analysis [9]. NMR is also highly reproducible, non-destructive,
quantitative, is useful for untargeted analysis [9]. Recent studies have utilized NMR
successfully to study metabolites in urine [10–14], serum [11,15–18], cancerous cells
[19–22], and cerebrospinal fluid [23–26]. However, the major drawback to using NMR
for metabolite analysis is that it is not as sensitive as GC-MS or LC-MS and many low
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abundance species are not identified [27].
Metabolite compound identification with LC separation is not without its
complications either. Identification in complex mixtures often relies on retention time
matching, UV or fluorescence profile matching, and/or mass fragment matching to
known standards [28]. Matrix effects can often complicate compound identification, for
example, by changing the retention time or forming adducts with substances within the
matrix [28]. Untargeted metabolomic analyses are challenging due to not knowing what
metabolites may be of interest in a sample [29,30]. In this regard, using a systems
biology approach and examining the genes and proteins in addition to the metabolites,
researchers can anticipate what metabolites may be of interest.
Library matches for ion fragments from LC-MS/MS analyses are difficult because
ion fragmentation energies differ from instrument to instrument due to dependence on
instrument geometry [31–33]. The resulting ion fragmentation pattern of the same
compound at the same normalized collision energy will often differ from a quadrupole to
an ion trap instrument, for example.

Additionally, matrix effects from the sample,

extraction medium, or mobile phases and even the type of collision gas used can
influence how a metabolite will fragment after LC separation [31–33].

There are

databases that contain fragmentation patterns of various metabolites at different collision
activation voltages, in different collision gasses, and on different instruments [34].
Unfortunately, these databases currently contain a small amount of compounds and rely
on users to supplement the database with their own compounds. Further complicating
matters is that ion fragmentation patterns and the intensities of the fragment peaks may
not be reproducible from one matrix to another [35].
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LC separations also have difficulty in separating isomeric and isobaric
interferences [29,30].

Multistage tandem mass spectrometry (MSn) is helpful for

discerning isomeric and isobaric species, but is not amenable for all compounds [34].
Ion mobility spectrometry (IMS) can be useful in separating isomeric and isobaric species
[36–41]. Ion mobility is a gas-phase separation technique which allows ions to separate
by their collisional cross section (CCS) and charge state. Like LC-MS/MS libraries, IMS
libraries are in their infancy and CCS values contained within are dependent on the type
of buffer gas used among other factors [42–44]. Furthermore, inconsistencies are noted
with calculated CCS depending on the type of mobility separation employed.

For

example, drift tube (DTIMS) CCS values may differ from those calculated with traveling
wave (TWIMS) devices [45]. TWIMS devices must be calibrated and if the calibrant
used has substantially different properties than the analyte of interest, discrepancies may
arise in the calculated CCS compared to the actual CCS [45]. A new IMS-MS approach
is introduced in this work employing mobility separations to improve peptide and small
molecule identification (Chapter 6).

5.2 – LC-MS/MS metabolomic analyses software shortcomings
Multiple software programs were utilized in our metabolomics work, with the
goal that subsequent versions would be able to more confidently identify the metabolites
within these samples. One of the first software programs used for this work was Sieve (v.
2.2.58 SP2, Thermo Fisher, San Jose, CA), followed by Mass Frontier (v. 7.0.5.9 SR3,
Thermo Fisher, San Jose, CA), and Compound Discoverer (v. 1.0.0.692, Thermo Fisher,
San Jose, CA). Also used in this work was the free software XCMS Online (v. 3.05
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Scripps Research Institute, La Jolla, CA), and a trial version of Elements for
Metabolomics (v. 1.2.1 Proteome Software, Portland, OR).
Sieve software has the advantage of being able to search the ChemSpider library
and the KEGG pathways. Raw data files from Thermo instruments can be directly
uploaded into Sieve for analysis and batch processed. Sieve also allows the user to
perform spectral alignments and statistical analysis including PCA. One drawback is that
compounds are matched based on exact mass matching rather than fragment ion matches.
Users must pour through data and decide if the compound assignment is relevant to the
analysis or not. For example, for the metabolomics analysis presented in Chapter 2 (TiO2
rat plasma), the data from Sieve had to be sequentially examined in order to remove any
compounds identified as pharmaceuticals or phytochemicals because of their propensity
to be false positive assignments.

After evaluating the data for false positives and

irrelevant compounds, approximate polarities and elution orders from literature sources
were utilized to further refine the results. This proved to be a long and arduous task.
Mass Frontier software has the capability to identify compounds by MS/MS
fragmentation. Currently, the library associated with Mass Frontier contains over 2000
compounds with both positive and negative ion mode libraries. Mass Frontier also has
the capability of allowing one to search identified compounds by class, spectral tree
similarities, molecular formula, m/z, and retention time. Despite the advantages of this
software over Sieve, it is only useful for analysis of pure compounds [46].
Compound Discoverer 1.0 has a similar layout to Proteome Discoverer where
users can create custom workflows to meet specific data analysis needs. Users can
directly import raw Thermo data files into the program for analysis. The BioNano
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Research Facility (BNRF) at West Virginia University purchased this as an upgrade for
Mass Frontier with the promise to fill the gap for untargeted analysis. Unfortunately, the
database from Mass Frontier did not transfer over to Compound Discoverer 1.0 and
instead requires the user to import or create user database. Databases from NIST and the
Human Metabolome database were downloaded, but despite being the correct file type
(.xml), the data within the files was not formatted correctly for integration into
Compound Discoverer 1.0. Compound Discoverer 2.0, in addition to allowing users to
create databases, has the added capability of searching mzCloud, KEGG, or Chemspider
databases. This program can evaluate isotopic distributions and high mass resolution of
compounds in order to determine elemental composition of compounds. Users can also
perform descriptive statistics, PCA, and differential analysis on the results. The BNRF is
currently evaluating an upgrade to Compound Discoverer 2.0.
XCMS Online is free online metabolite identification software and was used to
identify metabolites found in the tau mice (Chapter 4).

However, prior to sample

analysis, data must be converted from the raw data format to mzML format, which is
performed by a separate, but free program called MSConvert. Compounds are identified
from the METLIN database, also maintained by the Scripps Institute, which has
fragmentation spectra generated at 10, 20, and 40 eV. Although it is useful to have
spectra generated at multiple fragmentation energies, the spectra may not always be
comparable across platforms (see section 5.1). Compounds identified by XCMS Online
are given a score based on how well the experimental result matches the library result.
Reports are generated for both MS spectral matches and for MS2 spectral matches. The
output also includes PCA plots of the compounds for the samples. A cloud plot is also
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provided with the output, such as that shown in Figure 5.1, which visualizes the
chromatographic location of the ions, their masses, and their intensities.
Elements for Metabolomics is relatively new software, and one of the more
attractive features of this program is that it allows for direct import of data files without
file conversion from various MS vendors (e.g. Thermo and Waters). Features within the
chromatograms are identified and matched against NIST, HMDB, and user-created
libraries. Identified compounds are scored based on how well the experimental MS and
MS/MS data matches the library data. One advantage is that there are fewer identified
compounds that are unlikely matches. However, users are still required to examine the
data to ensure that compound matches are coherent. For example, pharmaceutical
compounds should not be included in the results if they were unlikely to be present in the
model organism. This software program was used to identify metabolites in the plasma,
vasculature, and aorta from TiO2 exposed rats (Chapter 3).
Despite these various software programs, the confidence in metabolite
identifications was still not sufficient to publish the metabolite data with the proteomics
data (Chapters 2, 3, and 4). Furthermore, when the metabolite data was included with the
proteins and input into Ingenuity Pathway Analysis (IPA), the resulting pathways only
differed slightly in the p value compared to results using the proteins alone. That is, the
input metabolites improved IPA results, but only marginally. Therefore, only the proteins
were used as inputs for published results rather than the combination of proteins and
metabolites.

5.3 Improvements on the horizon
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There has been a push within the metabolomics community to create better and
more freely available databases.

One such project is MassBank of North America

(MoNA) created by the Fiehn laboratory at the University of California at Davis [47].
Users are able to upload their own characterized compounds into the database and can
rate the quality and accuracy of the compound identification. The database contains
experimental and in-silico spectra. Data are curated with metadata describing the origin
of the data, which instrumentation was used to generate spectra, the ionization mode
utilized, the compound exact mass, the precursor mass used for fragmentation, the type of
precursor ion (e.g. [M+H]1+), and the level of fragmentation shown (e.g. MS2 or MS3).
Metadata also includes an ion peak table containing the fragments and their intensities.
Currently, the database contains over 205,000 spectra, separated into different groups
according to the type of spectra (e.g. high resolution or low resolution), phytochemicals,
human metabolites, and fatty acids. Although this database would appear to be very
promising to analyze the data described in Chapters 2, 3 and 3, there was no tool
available on the MoNA website to batch identify unknown compounds [47].

The

database was also downloaded, but could not be incorporated into Compound Discoverer
1.0. Although the downloaded database was the correct type of file (.xml), the data was
not formatted correctly within the file to be read by Compound Discoverer.
mzCloud is another freely accessible database for metabolite identification [48].
Like MoNA, mzCloud contains many spectra of compounds at different collision
energies and MSn levels.

Data is curated using information associated with the

compound name and synonyms, structure, annotated peaks, adduct information, and even
the laboratory of origin.

The mzCloud database is able to be searched either as a
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standalone web-based database or it can be searched within Compound Discoverer 2.0
[48].
With improvements in software packages and databases, users will be able to
more easily identify unknown and untargeted metabolites within their datasets. Projects
like the MONA database encourage collaboration and free sharing among scientists in the
pursuit of advancing science without cost prohibition. However, improvements must be
made for the ease of incorporating these databases into existing software programs.
Identifying compounds by precursor ion fragmentation alone is not sufficient for
high-confidence assignmnets. Additional parameters, such as retention time matching,
are required for compound identification. One parameter that is gaining traction for
compound identification is ion mobility in addition to fragmentation data [49].

As

mentioned in section 5.1, IMS is able to separate isomers and isobars [36–41] for which
co-elution is a hindrance to compound identification by LC-MS alone. IMS CCS
compound libraries have already been established and are expanding [42–44].
Furthermore, additional techniques can be coupled with IMS-MS to garner even more
information about an ion. For example, gas-phase hydrogen/deuterium exchange (HDX)
coupled with IMS-MS has demonstrated different rates of exchange of labile hydrogens
on ions of different compounds [50–55].

The extent of hydrogen/deuterium (HD)

scrambling through ion activation has also been shown to differ according to the amino
acid sequence of a peptide ion [56–59] and the type of charge carrier [56,60,61]. Becuase
the amount of deuterium uptake and scrambling depends on the analyte characteristics,
these are ideal analytical parameters to utilize for further characterization of compounds.
Chapter 6 presents a proof-of-principle analysis in which HDX, HD scrambling with
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HDX, and ion fragmentation are considered as compound identification parameters.
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6.1 Introduction
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a technique
often used for untargeted metabolite analysis [1,2]. It allows for concurrent separations
of many different classes of compounds whereas techniques, such as GC-MS, are better
suited for volatile compounds and often rely on a derivatization step prior to analysis [1].
LC-MS/MS is also more sensitive compared to other approaches such as NMR which
may not be able to detect low abundance species in complex mixtures [1,2]. However,
one of the challenges of LC-MS/MS is its ability to distinguish between isobars and
isomers that are not well separated by LC [2,3]. Ion fragmentation is one technique used
to identify differences in isomeric and isobaric species [4], but in the case of co-eluting
compounds, it may be difficult to discern fragments from one species from the other.
Additionally, fragmentation of isomeric species often produces ions of the same mass
requiring multistage tandem mass spectrometry (MSn) for identification [5–7]. Another
approach gaining in usage for ion identification is the determination of molecular formula
from accurate mass matches [8–11]. That said, accurate mass matching often requires
separations steps to remove interfering isomeric and isobaric species [11,12]. It is also
noted that this approach requires costly, high-end mass spectrometers.
Ion mobility spectrometry (IMS) has proven to be useful in separating isomeric
and isobaric species [13–18]. IMS is a gas-phase separation strategy which is achieved
through differences in ions’ collisional cross sections (CCS) and charge. Overall, ions
that are more compact and more highly charged traverse the mobility region more rapidly
than ions that are more elongated and have lower charge states [19,20].

Mobility

separation of compounds occurs on the millisecond time scale, whereas LC separations
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occur on the minutes to hours timescale. Thus, it is possible to separate ions in complex
mixtures on much shorter timescales. That said, because of the correlations between ion
CCS and mass, the combined IMS-MS peak capacity can be less than that of LC-MS
[21].
Gas phase hydrogen/deuterium exchange (HDX) can be coupled to IMS to further
differentiate ions based on deuterium incorporation (uptake). Gas-phase HDX is often
used as a tool to examine protein ion structure and conformational changes [22–29], but it
has also been used to study small molecules [30–34]. The exchange of hydrogens for
deuterium atoms with D2O reagent gas at labile sites (charge sites and other heteroatoms)
occurs via a relay mechanism [35]. It has previously been shown that the overall rate of
deuterium uptake varies in proteins, peptides, and small molecules [35–40], and in the
case of peptides, the uptake is dependent upon the amino acid sequence [41]. The
resulting mass spectra show differences in the isotopic distribution that could be
advantageous to use in pattern recognition for small molecule identification. Such uptake
patterns are dependent on the partial pressure of D2O gas and the overall HDX reaction
time [40]. Because at set partial pressures of D2O and electric fields ions experience the
same number of collisions with the reagent gas from sample to sample, the uptake
patterns of individual molecules are expected to be reproducible. They therefore provide
a means of compound identification.
Hydrogen/deuterium (HD) scrambling, or rearrangement of labile hydrogen and
deuterium atoms occurs with the addition of energy which statistically reapportions the
incorporated deuteriums. This can be troublesome when examining protein structures
[41–43]. The phenomenon is described by the “mobile” proton theory in which
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collisional activation results in significant proton mobilization [44,45]. This process can
be minimized by other fragmentation techniques such as electron capture dissociation
(ECD) [46,47], electron transfer dissociation (ETD) [48–50], and matrix assisted laser
desorption/ionization in-source decay (MALDI ISD) [51,52].

Several studies have

determined that HD scrambling on peptide ions should be dependent upon the amino acid
sequence [41,44,53,54] and the type of charge carrier (H+ compared to Na+) [41,55,56]
and is independent of the type of mass spectrometer used (Q-TOF vs. ion trap) [41].
Because HD scrambling has been shown to be dependent on the analyte itself, this
characteristic may be exploited as an additional parameter to further differentiate
metabolites without the use of LC separation.

In the study described here, HD

scrambling is used to repopulate some exchange sites with hydrogens which can then
undergo gas-phase HDX resulting in an overall increase in the amount of incorporated
deuteriums.
The reproducibility of IMS, HDX, and HD scrambling with HDX measurements
is particularly important when using such parameters for compound identification. Highreproducibility provides the opportunity to “dial in” these parameters across many
samples using select measurement conditions. For set separation and activation electric
fields in the drift tube, the overall reproducibility of these measurements requires that the
partial pressures of the buffer gases remain relatively constant within an experimental run
and from run to run.
Herein, a strategy that utilizes IMS, HDX, and HD scrambling with HDX is
proposed in order to rapidly distinguish compounds in a complex mixture. The approach
is evaluated for its ability to provide unique parameters for identification as well as for its
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overall reproducibility. The former evaluation addresses issues with regard to limited
peak capacity while the latter indicates feasibility with regard to automated pattern
matching. Although the demonstration reported here has been performed using relatively
rudimentary control of reagent gas partial pressure and model systems, the ion
distinguishing and reproducibility characteristics of the approach suggest the possibility
of incorporation into routine ‘omics workflows in the future.

6.2 Experimental
Materials. LC-MS grade water, acetonitrile, formic acid, and acetic acid were
purchased from Sigma-Aldrich (St. Louis, MO). D2O (99.9% D) was purchased from
Sigma-Aldrich (St. Louis, MO). Ammonium bicarbonate (≥ 99.5%), urea (ACS reagent
grade), bovine serum albumin (BSA, 98.0%), dithiothreitol (DTT, ≥ 99.5%),
iodoacetamide (IAM, ≥ 99%), cysteine (≥ 98.5%), trypsin (from bovine pancreas, TPCK
treated) were also purchased from Sigma-Aldrich (St. Louis, MO). Bradykinin (≥95.0%),
substance P (≥95.0%), and synthetic peptide KKDDDDDIIKKII (KKD peptide, 94.1%)
were all purchased from GenScript (Piscataway, NJ). These materials were used without
subsequent purification.
Sample Preparation for reproducibility studies. BSA was solubilized in 200
mM ammonium bicarbonate with 6 M urea in water. BSA proteins were reduced with
DTT, alkylated with IAM, and quenched with cysteine. The proteins were then digested
with trypsin and desalted with Peirce C18 spin columns (Thermo Fisher, San Jose, CA).
This sample preparation has been described in detail previously [57]. Digested samples
were dried, reconstituted in 1:1 water: acetonitrile with 0.1% (v/v) formic acid, and then
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pooled for sample analysis. Pooled samples were loaded into a gas tight syringe, the
syringe was placed into a syringe pump and sample was infused at 300 nL/min through
the electrospray needle.
A mixture of model peptides containing 45 µg/mL bradykinin, 45 µg/mL
substance P, and 450 µg/mL KKD peptide was generated in 1:1 water: acetonitrile with
0.1% (v/v) acetic acid. Samples were loaded into a gas tight syringe for direct infusion
into the ion source.
Data collection and analysis. Data were collected on a home-built, dual-gating
IMS device coupled to a Thermo LTQ Velos mass spectrometer (Thermo Fisher, San
Jose, CA) which has been described in detail elsewhere [58]. The front gate was open for
a duration of 150 μs and the back gate was opened at a delay with respect to the first gate
for 200 μs. Ions were allowed to traverse the drift tube and then were collected in the ion
trap for 100 ms prior to mass analysis for each delay time setting. Data were collected
for 30 seconds at each drift time resulting in an averaged mass spectrum.
For sequential and random drift time data collection, a total of 3 sample sets were
collected. For sequential drift time data collection, the delay times sequentially stepped
through (5.0 ms, 5.2 ms, 5.4 ms, etc.) the drift time range. For random drift time data
collection, the delay times were randomized (7.8 ms, 6.2 ms, 10.4 ms, etc.). The order of
the type of acquisition was randomly assigned. The run order was: random, sequential,
sequential, random, sequential, random. The helium buffer gas pressure within the drift
tube was maintained at ~2.70 torr for reproducibility experiments. This pressure was
maintained in the drift tube for the duration of the data acquisition for the 6 trails.
For the HDX and scrambling experiments, the partial pressures of He and D2O
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were maintained at ~2.51 torr and ~0.02 torr, respectively. The reservoir containing the
D2O was maintained at a temperature of 35°C and the tubing from the reservoir to the
drift tube was heated to prevent D2O condensation which could lead to partial pressure
fluctuations. The HDX reproducibility sample sets using BSA digests were obtained by
randomly stepping through the delay times with 3 trials for each sample type. HDX
reproducibility studies using isotopic distributions after deuterium uptake were performed
on the model peptide mix without drift selection.

HD scrambling with HDX

reproducibility studies also were performed on the model peptide mixture without drift
time selection. A total of 6 replicates were performed for each HDX and HD scrambling
with HDX study using this sample. Between each trial, the drift tube voltage was
removed and the drift tube gases were evacuated. Care was taken to return the gas partial
pressures to the same approximate values by using the same leak valve settings
(Granville Phillips, MKS Instruments, Andover, MA).
Data from each IMS-MS dataset were compiled into a 3-column file (drift time,
m/z, and intensity). Peak intensity was normalized and then converted to log2 scale.
Two-dimensional (2D) contour plots of m/z verses drift time of the normalized, scaled
data were constructed using DPlot (v. 2.3.5.3, HydeSoft Computing, LLC; Vicksburg,
MS, USA). An in house peak picking algorithm was used to select the most intense
features by examining the change in intensity in separate drift time and m/z regions (~1
ms by ~4 m/z units). The peaks with normalized intensities greater than 1 were extracted
and then compared across the data collections. Data features corresponding to BSA
digest peptide ions were compared across replicate datasets to determine the
reproducibility in drift time. Coefficients of variation (CVs) were calculated for multiple
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BSA digest peptide ions.
Isotopic envelope reproducibly from a drift time distribution with HDX of BSA
digest peptides in a drift distribution with HDX was performed by a using an algorithm to
extract drift times and m/z around each peptide of interest. The dimensions of the
extraction box varied based on conformers proximity, the total number of isotopes, and
the charge state of the peptide ion. A drift time range of not more than 1 ms wide was
used. Ion intensities within the region were summed for each m/z bin (0.08333 units
wide) in the extracted region and then normalized by the total intensity of the region.
The root mean square deviation (RMSD) for each experimental run was compared to the
group mean.
Isotopic distribution reproducibility for HDX and HD scrambling with HDX
measurements for the model peptide mixture (bradykinin, substance P, and KKD peptide)
was examined without drift selection. HD scrambling was induced by collisionally
activating ions in the last portion of the drift tube (~0.9 m from the ion source).
Continued HDX was then allowed to proceed in the remaining portion of the drift tube
(~0.1 m). Six replicates of both the HDX and HD scrambling with HDX analyses were
collected. Between each trial, the mass spectrometer was set to stand by, the applied
voltage was removed, and the buffer gases were evacuated from the drift tube.
Subsequently the gases were reintroduced manually by dialing the leak valves to their
previous setting values. Thus, each replicate is essentially a new, "from scratch" data
collection. Isotopic distribution reproducibility was determined as described above for
the BSA digest. A separate demonstration examined the fragment ions produced by
peptide ions undergoing HD scrambling with HDX; the fragment ions were produced by
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collision-induced dissociation (CID) in the linear ion trap mass spectrometer. Isotopic
distribution comparisons were performed (RMSD values) for some of the resulting
fragment ions.

6.3 Results and Discussion
Deuterium uptake for distinguishing molecules.

As mentioned above, the

ability to utilize a distinguishing measurement relies on its probing of a separate
physicochemical property of the ion. With regard to gas-phase HDX using D2O reagent
gas, the property is labile site accessibility which has been interpreted as accessibility to
charge site and the ion’s surface (collisions with D2O) [35,40,50,59–61]. With different
arrangements of charge sites and heteroatoms, a large number of polar compounds should
exhibit different HDX characteristics. To demonstrate the nature of gas-phase HDX as a
compound-specific measurement, a model peptide mixture is here used to provide
examples of different HDX behavior. Notably, the use of HDX to increase the overall
peak capacity of the measurement in this manner is similar to seminal studies that
employed parallel dissociation [62,63] and drift shift reagents [64–66] to disrupt the
correlation between IMS and MS measurements.
Unique deuterium uptake patterns of the different peptide ions were observed for
the model peptide mixture (Figure 6.1). For example, for the [M+2H]2+ ions of substance
P, little to no deuterium (<1) uptake is observed as shown in Figure 6.1A. In contrast, for
[M+2H]2+ bradykinin ions from the same experiment, Figure 6.1B shows that, on
average, the [M+2H]2+ bradykinin ions incorporate ~3 deuteriums. For the [M+3H]3+
KKD peptide ions, the average deuterium uptake is ~12 deuteriums (Figure 6.1C).
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For these experiments, the partial pressure of D2O is sufficient to exchange the
rapidly exchanging sites (readily accessible) [36,67–70]. To examine the origin of the
differences in deuterium incorporation (Figure 6.1), it is instructive to consider the
numbers of exchangeable hydrogens on these peptide ions. There are 5 residues on
substance P (RPKPQQFFGLM) containing side-chain exchange sites namely: 1 arginine;
1 lysine; 2 glutamines; and, 1 methionine. Therefore, including these sites and those at
the backbone amide, amino- and carboxy-termini, and the two extra protons, the total
number of exchangeable hydrogens is 24 for [M+2H]2+ substance P ions. In comparison,
there are 19 and 31 exchangeable hydrogens for the [M+2H]2+ bradykinin and [M+3H]3+
KKD peptide ions, respectively. In comparing the two doubly-charged ions, the percent
deuterium incorporation for substance P and bradykinin is 4.2% and 15.8%, respectively.
This translates into nearly a four-fold efficiency increase for the bradykinin ions.
Therefore, although the ions have the same number of charges and nearly the same
number of residues and exchangeable hydrogens, they exhibit significantly different
deuterium incorporation capabilities. Presumably this is a reflection of differences in
exchange site accessibility to charge sites and surface collisions (i.e., the ion structures)
[71].

Overall, the triply-charged KKD peptide ions exhibit the greatest efficiency

(38.7%) in gas-phase HDX (nearly double that of the bradykinin ion).
Reproducibility of drift time in HDX experiments. In order to take advantage
of spectral matching for peptide ion assignment, it is requisite that drift time distributions
resulting from experiments using the buffer gas mixture are highly reproducible. Indeed,
such spectral reproducibility is a strength of metabolite assignment using GC-MS data
where the fragmentation spectra from electron ionization (EI) are extremely consistent.
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Admittedly, the instrument used in these experiments (described in Donohoe, et al.[58])
uses a longer gate time at the back of the drift tube compared to the front (200 µs vs. 150
µs). This is required because of the relatively lengthy second gate (~3 mm). That is, a
longer time is required to allow the ions to fully traverse the distance of the second gate
and any extra region caused by impinging fields during the off-transmit setting. Thus, in
order to determine if gating differences effect the measurement reproducibility, data were
collected by sequentially (5.0 ms, 5.2 ms, 5.4 ms, etc.) or randomly (7.8 ms, 6.2 ms, 10.4
ms, etc.) stepping through the drift times using a buffer gas of He only. Three replicates
each of the sequential and randomized drift time acquisition were performed in a random
order for a tryptic digest of BSA. The average CV for peptide ion peaks is determined to
be 1.7 ± 0.5% (data not shown). This analysis serves as the benchmark against which the
drift time reproducibility of peptide ions in the buffer gas mixture (He + D2O) is
compared.
There is a notable shift in the drift times for features that appears to slightly
increase with time and is fairly consistent across the whole drift time distribution. This
shift correlates with a slight increase in drift pressure over time which likely results from
the relatively simplistic gas introduction system (see section 5.2 above). Although this
can be corrected when calculating a collision cross section, it could present a challenge in
rapid drift time database comparisons. That said, the reproducibility is similar to that
reported in other IMS instruments [72–74].

It is noted that the high reproducibility

observed for the random selection of delay times demonstrates analytical utility in that
selection times may be used for targeted analyses.
Variability in buffer gas pressure is a greater concern with the buffer gas mixture
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considering that only a small percentage of the composition is D2O. Therefore, a small
change in partial pressure could result in large changes in drift times. This could be a
significant source of error especially for a system that utilizes an evaporative introduction
system employing a leak valve such as is used here. The purpose of the following
experiments was to determine how much the drift time reproducibility deviates from the
benchmark values upon using the buffer gas mixture. Figure 6.2 provides an indication
of the run-to-run variability in drift time for BSA digest peptide ions that undergo HDX
in the drift tube. Dataset features for [M+2H]2+ ions of the peptides RHPEYAVSVLLR
and LGEYGFQNALIVRYTR show some difference in drift time (Figures 6.2A and
6.2B). However, the CV of these peaks across the 3 replicates is 1.2% and 1.3%,
respectively (Figure 6.2C).

Separate dataset features examined in the drift time

distributions of the BSA sample were found to have average CVs of 1.4 ± 0.1% (Figure
6.2C). The reproducibility is not significantly different (CVHe = 1.7 ± 0.5%, CVHe +D2O
1.4 ± 0.1%, p=0.68, α=0.05) when separately dialing in the buffer gas mixture
components with the leak valves. This is still within the acceptable reproducibility range
of IMS experiments.
Reproducibility of deuterium uptake in HDX experiments. As with the drift
times, comparisons of HDX reactivity reproducibility can be achieved with spectral
comparisons.

Here, due to the presence of multiple isotopologue ions, a RMSD

comparison has been employed.

To best illustrate the reproducibility, results for

[M+2H]2+ bradykinin ions from the peptide mixture are presented in Figure 6.3. In these
experiments, data were collected and the MS instrument was set to standby, the drift tube
voltage was removed, and the buffer and reagent gases were evacuated between each run
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by turning down (and then off) the leak valves. This was done in order to determine if
high-reproducibility could be achieved from a “new” start of the instrument. Figure 6.3
shows the isotopic distribution of the [M+2H]2+ bradykinin ions across the 6 trials. The
RMSDs of the trials were less than 0.2%. The RMSDs of the other peptides within the
model peptide mix were also determined for the [M+2H]2+ KKD peptide and substance P
ions; [M+3H]3+ bradykinin, KKD peptide, and substance P peptide ions; and the
[M+4H]4+ KKD peptide ions. The RMSDs were all found to be less than 1% (data not
shown).
A question arises as to whether or not comparisons of such isotopic distributions
could be of utility for complex mixture analysis. Here, it is noted that the highlyreproducible drift time separation (Figure 6.2) is useful. That is, in mobility separation
experiments, it is possible to select for dataset features and obtain the high reproducibility
of the isotopic distributions demonstrated for the bradykinin ions. For example, mobility
selection

of

the

features

associated

with

[M+2H]2+

ions

of

the

peptides

RHPEYAVSVLLR and LGEYGFQNALIVRYTR (Figures 6.2A and 6.2B) have resulted
in isotopic distribution RMSDs that are less than 1% (data not shown) in the triplicate
analyses described above. Therefore, the mobility and reactivity information together can
be used for compound matching provided that the isotopic distributions of other species
in complex mixtures do not shift and interfere with that of the desired analyte.
Isotopic distribution reproducibility after HDX and HD scrambling with
HDX. One issue in determining ion identities in the manner proposed here is whether or
not there is a sufficient number of identifiers to obtain high-confidence assignments.
Ideally increased parameterization (separate measurements) would be required to address
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mixtures of greater complexity.

A question arises as to whether or not additional

measurements can be made with the existing instrumentation that would provide unique
ion characterization. One approach could involve the use of HD scrambling followed by
HDX.

It is instructive to consider that the “mobile proton” model for peptide ion

dissociation [44,45,75,76] accurately describes HD scrambling [41,77].

Collisional

activation causes intramolecular proton transfer events where a severing of a chemical
bond can occur at the site of proton transfer. Because deuterons can be mobilized as well
as protons, HD scrambling can follow collisional activation. HD scrambling offers an
opportunity in that hydrogens can be scrambled to accessible sites and deuteriums can be
scrambled to sites less accessible by HDX. Therefore, more extensive deuterium uptake
can occur as the newly populated sites with hydrogen undergo subsequent HDX.
To test the reproducibility of a process in which ions are subjected to HDX and
then HD scrambling with subsequent HDX, experiments were performed for the peptide
mixture sample as outlined in the Experimental section. As with the other studies, the
drift voltage and activation voltage were removed between runs and the drift gases were
evacuated and then reintroduced. Figure 6.4 shows the effect of HD scrambling with
further HDX on the same peptide ions from the model peptide mixture shown in Figure
6.1. Figures 6.4A and 6.4B demonstrate that even with ion activation there is little to no
further deuterium incorporation for the [M+2H]2+ substance P and bradykinin ions.
Figure 6.4C shows that [M+3H]3+ KKD peptide ions incorporate significantly more (~3
to 4) deuteriums after scrambling.

The isotopic distribution RMSDs for the 6 HD

scrambling trials of the peptide ions shown in Figure 6.4 were less than 1% also
demonstrating suitable reproducibility for routine use in ion identification analyses.
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Reproducibility in experiments using HDX and HD scrambling with HDX
followed by CID. As a final ion descriptor, it is useful to consider ion fragmentation in
conjunction with the HDX and HD scrambling with HDX processes. Such an approach
derives conceptually from parallel dissociation methods performed using ion mobility
devices [62,63]. Here, although CID results in HD scrambling, the fragmentation process
would provide reproducible ion fragmentation spectra as well as isotopic distributions for
fragment ions. Furthermore, given that HDX provides a sufficient shift in m/z value, ion
fragmentation could allow for further disambiguation of sample peaks within the same
drift time window.
The model peptide mixture was subjected to HDX combined with HD scrambling
with HDX. Then a peak at a drift time of 6.7 ms and having m/z 526 corresponding to
extensively deuterated [M+3H]3+ KKD peptide ions was selected (mobility and m/z) and
the precursor ions were subjected to CID in the linear ion trap at a normalized collision
energy of 40. Three replicates were collected and, as before, between each replicate the
drift and activation voltages were set to zero and the buffer gases evacuated from the drift
tube. Figure 6.5A presents the MS/MS spectra for the [M+3H]3+ KKD peptide ions.
Notably the ion fragmentation spectra are very similar as may be expected from the
highly reproducible process of CID [78]. For example, the relative intensities of the
identified y-ion series are very similar across the fragmentation spectra. Figure 6.5B
shows an expanded region of the fragmentation spectra encompassing the isotopic
distribution of the y122+ fragment ion. The isotopic distribution was found to be highly
reproducible (RMSDs < 1%) for the y122+ fragment ion (Figure 6.5B). Other identified
fragment ions exhibited a similar RMSD (data values not shown).
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Although

the

experiments

described

above

provide

proof-of-principle

demonstrations of combined IMS-HDX-MS/MS approaches for obtaining information
that could serve as unique identifiers for ions, the discussion has thus far not addressed
the timescale of these measurements. Admittedly, the combination of IMS with the
scanning MS approach results in a relatively long timescale measurement (e.g., MS are
collected at separate delay time settings). The IMS-MS data reported here required
timescales of tens of minutes for this instrumentation geometry. That said, all of the
measurements shown here can be performed on an instrument that combines IMS with
time-of-flight (TOF) MS where the MS measurement is nested in the IMS experiment
[79]. Additionally, parallel CID can be conducted for such an instrument at no cost to
experimental run time [62,63]. Thus it would be possible to make these measurements on
the seconds timescale. Consider experiments in which drift times and m/z values could
be recorded in 5 seconds for which He is employed as a drift buffer gas. Then these
values could be recorded for 5-second experiments in which a He and D2O buffer gas
mixture is used. Next the m/z shift could be determined in a 5-second HD scrambling
with HDX experiment. Another 5 second experiment could be used to perform parallel
CID. Overall, 20 seconds of instrumentation time could produce these six pieces of ion
identification information. This is a significant time savings compared with condensedphase separations.

6.4 Conclusions
The experiments described here provide proof-of-principle examples of how IMS
combined with gas-phase HDX and MS analysis techniques can be used to provide
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information-rich datasets. Such datasets could have a number of unique ion descriptors
to be used in identification efforts for compounds in mixtures such as those encountered
in ‘omics analyses. The studies show that sufficient reproducibility can be obtained for
these descriptors such that ion identification could be achieved through comparisons with
values recorded for molecular standards. Although such an approach would require a
Herculean effort to populate such databases, the rapidity of the measurements would
allow for significant improvements in sample throughput which is a significant challenge
for biomarker discovery efforts. In addition to the database challenge, scoring schemes
would need to be devised for providing an assessment of confidence in ion matches.
Although important, such strategies could benefit from algorithms developed previously.
For example, scoring isotopic distribution matches could be achieved using an approach
that is similar to the cross correlation approach employed by the SEQUEST software
suite used in proteomics experiments [80]. Finally, although the peptide systems utilized
here provided a simple means for proof-of-principle studies, the approach should be
suitable for ions of other electrosprayed compounds. This would include negativelycharged species because the relay mechanism for exchange with D2O [81,82] as well as
intramolecular proton transfer [83] should be operative in these ions. The approach may
even be extended to include other descriptors such as exchange of aliphatic hydrogens at
elevated drift tube temperatures [84]. In the near future, studies will be presented that
demonstrate the approach for other metabolomics compounds.
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Future Directions
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7.1 Proteomic Analyses
7.1.1 TiO2 NP exposed rats. The affected biopathways identified in Chapters 2
and 3 begin to shed light on the connection of systemic inflammation to the observed
changes in the arterial vasodilation response. Observed differences in the significant
pathways of vascular tissue compared to plasma and aorta tissue suggest the tissues can
respond dissimilarly to the TiO2 exposure. However, it is unclear if this is due to spatial
differences from the location of NP introduction, to temporal differences in the tissue
response, or to functionality differences of the tissues, all of which occur by different
mechanisms of toxicity.
Future proteomic studies to examine spatial differences should include additional
resistance vascular tissue further downstream from that examined in Chapter 3 in order to
determine if the response of the vascular tree is similar throughout or if there are changes
as a result to the proximity to the particle introduction site. Rats should also be examined
at multiple time points after exposure to examine temporal deviations in response.
Various studies have examined changes in protein concentrations or gene expression as a
result of TiO2 NP exposure at various time points. For example, studies have been
conducted at 1, 2, 8, 16, 30, and 90 days post exposure [1]; at 1 and 70 days post
exposure [2]; at 5 days post exposure [3]; and at 1, 3, and 28 days post exposure [4].
Examining variations in the protein levels over time would also allow for information to
be gathered on what metabolic pathways are being altered over time and relate this
information to the physiological response. This could provide information as to whether
vasodilation response returns to normal, what metabolic processes are involved, and
when this occurs post-exposure.
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7.1.2 ICV-STZ treated mice. Although protein concentration changes were
observed as a result of the ICV-STZ treatments, none were found to be significant. In the
work presented here, mice were given a single dose of STZ at a concentration of 3 mg/kg.
Cognitive analysis was performed at 3.5 months post treatment and the animals scarified
at 4 months post treatment [5]. Other studies used the same dose but examined rats for
cognitive changes at 14 days post ICV-STZ treatment [6] and at 30 days post ICV-STZ
treatment [7]. A different study examining cognitive changes in rats also utilized 3
mg/kg concentrations of STZ, but the STZ was administered twice, 48 hours apart [8].
Yet other studies have administered large doses of STZ to rats, 55 mg/kg [9] and 150
mg/kg [10], to determine the effect on tau phosphorylation, as higher degrees of tau
phosphorylation are more strongly associated with cognitive decline [11]. Future studies
should examine if different doses, a singular dosage, or multiple dosages would induce
the early metabolic changes observed in AD. Furthermore, examining the animals at
different times post ICV-STZ treatment might demonstrate marked metabolic changes.
The bottom-up proteomic analyses performed on the TiO2 exposed rats and the
ICV-STZ treated tau mice can be supplemented by additional proteomic techniques. For
example, multidimensional protein identification technology (MudPIT) utilizes strong
cation exchange (SCX) coupled with reversed phased (RP) chromatography separations
to enhance peptide identification [12,13].

Examination of protein post translational

modifications (PTMs) can provide valuable clues as to the protein activation state or the
progression of a disease state [14]. Furthermore, isotopic labeling techniques allow for
multiplexing of samples reducing the overall instrument analysis time and decreasing the
run to run variability [15].
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7.1.3 Multidimensional protein identification technology. In 1999 the Yates
group described direct analysis of large protein complexes (DALPC), where two types of
chromatography, strong cation exchange (SCX) and reverse phase (RP), are used in
tandem to separate peptides based on different chemical properties followed by mass
spectral identification [12]. By using 2 orthogonal types of chromatography, the
researchers were able to increase peptide separation aiding in the identification of more
peptides [12]. Similar to gel-based techniques, the SCX column separates peptides based
on the isoelectric point of the peptide determined by the amino acid sequence. Typically,
buffer solutions of increasing strength are applied to the SCX column and the salt ions
displace the bound peptides. Peptides with low isoelectric points will elute first and
peptides with high isoelectric points will elute later. The peptides are then subject to RP
separation eluting the peptides based on decreasing polarity. After elution from the RP
column, peptides are analyzed by mass spectrometry [12]. In the DALPC iteration,
fractions were collected and then loaded onto the RP column [12]; however, this was
later refined to elute peptides directly from the SCX column onto the RP column, a
technique known as MudPIT (Multidimensional protein identification technology) [13].
These techniques were applied to analyze the Saccharomyces cerevisiae ribosome [12]
and yeast proteome [13] and were able identify novel proteins and low abundance
proteins within the samples [12,13].
The MudPIT technique applied to the projects in this work would be of particular
interest to identify low abundance proteins such as kinases and transcription factors.
Additionally, since there is a large dynamic range in the concentration of plasma proteins
even after immunodepletion [16], 2D orthogonal separations would be useful in
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discerning plasma peptides not identified in 1D RP separations.
7.1.4 Post translational modifications.

PTMs can affect the structure and

function of proteins [14]. In addition to bottom-up proteomics methods, PTMs analysis
would provide greater insight into understanding metabolic processes within a biological
system. For example, phosphorylation is a common modification to activate or inactivate
proteins by a kinase or a phosphorylase adding or removing, respectively, a phosphate
group from a serine, tyrosine, or threonine residue.

The relative ratio of a non-

phosphorylated protein to a phosphorylated protein can provide clues as to whether a
pathway is up or down-regulated [14]. Analysis of phosphorylated proteins and peptides
requires an enrichment step prior to analysis by mass spectrometry due to their low
abundance [17].

There are many different enrichment options available including

fractionation techniques, such as hydrophilic interaction chromatography (HILIC), strong
cation exchange (SCX), or strong anion exchange (SAX); or enrichment techniques based
on compound affinity, antibodies, or covalent modifications (as reviewed in reference
[17]).
Another PTM of interest is methionine oxidation, a modification which has been
shown to scavenge reactive oxygen species (ROS), to mark proteins for degradation, and
to take part in cell signaling [18].

Furthermore, methionine oxidation has been

implicated in a number of diseases including emphysema, cancer, and Alzheimer’s (as
reviewed in references [19,20]). However, methionine residues are readily oxidized
when exposed to air and unless samples are collected and prepared under an inert
atmosphere, results can be misinterpreted (as reviewed in reference [21]). As with
phosphorylated proteins and peptides, there are several options available to researchers
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for methionine oxidation enrichment including the use of antibodies, diagonal
chromatography, or simply looking for 16 Da shifts in mass spectral data [21].
Deamidation is another PTM that occurs on asparagine and glutamine residue
through removal of the side chain amine, converting these residues into aspartic acid and
glutamic acid, respectively. These changes can result in altered protein functionality and
have been implicated in human aging, Alzheimer’s disease, and cataract formation (as
reviewed by [22]). However, the rates of deamidation are dependent on the amino acid
residue sequence, the tertiary structure of the protein, and the environment that the
protein experiences [22]. One of the consequences of deamidation is the formation of the
isomers iso-aspartate and gamma-glutamate. Top down proteomic approaches, where
intact proteins are ionized and then fragmented, and bottom-up approaches, like those
used in this work, have been successfully used to characterize the residue-specific
locations of deamidation by searching for iso-aspartate and gamma-glutamate residues
[22].
7.1.5 Isotopically labeled protein quantitation. Relative protein quantitation is
a fast and simple method of analyzing relative changes between control and exposed
groups. However, changes in mass spectral ionization efficiencies from sample to sample
due to matrix effects or electrospray conditions add uncertainty to the results.

One

method of combating this is through the use of isotopic labeling. Gel based labeling
methods and isotopic labeling prior to mass spectral analysis are methods commonly used
for relative quantitation.
Difference gel electrophoresis (DIGE) is a technique that employs different dyes
that fluoresce at different wavelengths [23,24]. Dyes label 3 different protein sample
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sets, typically, a control sample, a treated sample, and an internal standard [24].
However, a third sample or a mixture of the two samples may be substituted for the
internal standard [23]. The 3 labeled samples are combined and analyzed by 2D gel
electrophoresis. Proteins are first separated by their isoelectric point and then separated
in the orthogonal direction by molecular weight [24]. The same protein from each sample
will migrate to approximately the same area on the gel, with slight differences due to the
different fluorescent tags. The gel is then analyzed 3 different times at 3 different
wavelengths to measure the protein concentrations based on the fluorescence intensity.
The advantage of this technique is that multiplexing samples removes the run to run
variation in running and analyzing gels compared to single sample gels [24].
Furthermore, 2D gel analysis has demonstrated the ability to separate over 10,000 protein
spots [25]. Although this multiplexing technique allows for simultaneous analysis of
different samples, multiple gels are still needed for statistical power [24]. Additionally,
2D gels methods are labor intensive and excision of the protein spots is required for
protein identification by mass spectrometry [23].
Isotope coded affinity tags (ICAT) and isobaric tags for relative and absolute
quantitation (iTRAQ) serve as means to isotopically label extracted proteins from
organisms prior to mass spectral analysis. The isotopic label allows for determination of
the relative amount of a protein in different samples when using a multiplex approach.
ICAT is a technique that covalently binds the isotopic tag to the sulfhydryl group on the
cysteine residues [26]. The tag consists of 3 parts: the thiol specific reactive group
attaches the tag to cysteine residues, the linker region which makes up the middle part of
the tag and contains hydrogens along a saturated carbon chain for the “light” label and
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deuteriums for the “heavy” label, and the biotin affinity tag for peptide enrichment by
affinity columns prior to analysis (see Figure 7.1). The “light” and “heavy” samples are
combined, digested, and then analyzed with a bottom-up proteomics approach. The
monoisotopic mass of the labeled peptide will be shifted from the monoisotopic mass of
the unlabeled peptide [26]. The result is the ability to perform relative quantitation of
proteins in two different samples at the same time. The comparison of the abundance of
the “heavy” and “light” labeled peptides occurs in the MS analysis and not the MS/MS
analysis [26].
One caveat to using this tag in LC-MS/MS experiments is the deuterium effect,
that is, changes in the elution time of compounds are observed due to the incorporation of
deuteriums [27,28]. Deuterium atoms will interact more with the C18 stationary phase
than hydrogens. In the case where the deuteriums are on polar functional groups, there is
less interaction with the stationary phase, and little to no change in elution time is
observed. However, when the deuterium atoms are located on non-polar groups, such as
in these ICAT tags, there is the possibility for interaction with the stationary phase
resulting in longer elution times compared to the hydrogen containing tag [27,28]. The
same research group that developed the ICAT tags modified them later to replace the
deuterium labels with 13C in the linker region to eliminate any observed deuterium effect
[29]. Therefore, this technique can be employed without consideration of the deuterium
effect.
iTRAQ was first developed as a means to expand isotopic labeling for
quantitation purposes from a binary system to a quaternary system [30]. Like ICAT,
iTRAQ contains 3 regions: a reporter group, which contains
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13

C and/or

15

N isotopes

detectable upon MS/MS fragmentation; a mass balance group, which balances the mass
of the reporter group so that the combined masses of the two regions are equal; and an
amine reactive group, which attaches the tag to the peptide (Figure 7.2). Protein samples
are digested and then labeled with one of 4 different iTRAQ tags on the N-terminal ends
and the side chains of lysine residues. The samples are then combined for MS/MS
analysis. Since the overall mass of each of the 4 labels is the same, the co-eluting labeled
peptides will have the same mass in MS analysis.

However, when the peptide is

fragmented, the iTRAQ tag is cleaved resulting in a neutral loss of the balance group and
charge retention on the reporter group. The reporter group will then be detected at 114,
115, 116, and 117 m/z and the peak areas of the reporter group correspond to the amount
of peptide in the associated sample [30]. After its initial development as a 4-plex system,
iTRAQ is also available as an 8-plex system [31].
One advantage to using isotopic labeling techniques is the increase in sample
throughput due to a reduction the overall instrument usage time compared to analyzing
samples individually. Another advantage is the improved statistical power as the run to
run sample error is reduced. However, the advantages of multiplexing are lost if there is
not a way to compare one multiplex to another. This is accomplished by duplicating
samples between multiplexes or using a standard protein or peptide in each multiplex.
Furthermore, multiplexing kits cost approximately $65 per sample and can be cost
prohibitive for some laboratories.

7.2 Metabolomic Analyses
Although untargeted metabolomics by LC-MS/MS is touted as a means to
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examine a wide-swath of compound classes, it is hindered by data analysis. There are
some promising software products on the horizon, but their efficacy has yet to be
determined. For a review of metabolite identification software used in this work and
upcoming software, refer back to Chapter 5. Until LC-MS/MS metabolite identification
software has reached the ease and reliability of current protein identification software,
researchers can use proteomic results to guide metabolomic studies. By understanding
affected protein pathways researchers can target metabolites acting as signaling
molecules or secondary messengers within pathways of interest. In cases where there is
limited sample available, a similar extraction scheme as used in Chapters 2 through 4
would prove useful in extraction of many different classes of metabolites. Unfortunately,
even with targeted analysis, standards are required in order to determine the ionization
efficiency of the compound, if it will co-elute with other compounds, and the
fragmentation pattern of the compound on a particular instrument with the desired
settings.

7.3 IMS-MS Instrumentation
The

IMS

strategy

described

in

Chapter

6

captures

ion

mobility,

hydrogen/deuterium exchange (HDX), scrambling, and fragmentation parameters of
different compounds in order to identify compounds within a complex mixture without
the use of chromatographic separations. Although the home-built instrument used in
Chapter 6 (and described in detail in reference [32]) demonstrated acceptable analytical
reproducibility of all parameters, the linear ion trap mass spectrometer was not the ideal
type of mass spectrometer for this type of analysis. Approximately 30 minutes was
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required to collect the data across the entire drift time distribution. Moreover, the ion
trap only allowed for a 100 Da sized window of fragmentation, which would greatly
increase the analysis time in order to collect all the fragmentation data for the entire drift
distribution.
New IMS-MS instrumentation is being developed in the Valentine laboratory with
a similar drift tube design, but replacing the trapping mass spectrometer with a dispersive
time-of-flight (TOF) mass spectrometer. A dispersive mass spectrometer would allow for
detection of all ions, not just the sequential collection of ions collected at different m/z
values. Additionally, a TOFMS would be able to incorporate parallel fragmentation
[33,34] and fragment all ions at once, unlike the 100 Da sized window in the linear ion
trap. By using a dispersive mass spectrometer, the total analysis time for a full drift time
scan is estimated to decrease from 30 minutes to 5 seconds, and thus, greatly increase
sample throughput.

7.4 IMS-MS Automation and Software
The new strategy described in Chapter 6 paired with the new instrumentation will
collect ion mobility, HDX, hydrogen/deuterium (HD) scrambling with HDX, and
fragmentation data on small molecules and peptides. With such a large amount of data
being collected and the current algorithms in use, it would be very tedious to compile and
analyze the data generated. Additional algorithms and software need to be developed to
help sift through all of the data. Furthermore, data from model proteins, peptides, and
compounds will be used to create searchable databases of known mobilities, uptake
patterns, and scrambling patterns. Similar to the development of RP retention time
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prediction algorithms [35–37],

algorithms for HDX and HD scrambling could be

developed to predict how compounds in the same class, or peptides based on their amino
acid sequence would react under various conditions. Furthermore, scoring algorithms
could be developed to compare experimental data to theoretical or library data for
compound matching. Existing software that may be of use is The Deuterator [38] and
HD Desktop [39], which determine the percent incorporation of deuterium [38,39] and
the later provides visualization and statistical analysis of data [39].
It is also important to examine how different post translational modifications
(PTM) would affect deuterium uptake and scrambling patterns. For example, a PTM
such as an amidation would not only add an additional charge site, but also create an
additional location for deuterium exchange to occur.

Phosphorylation of a serine,

threonine, or tyrosine would also add additional labile hydrogens. Acetylation, on the
other hand, has previously been shown to decrease the gas-phase basicity of arginine
[40].
Once the new instrument is brought online and automated data analysis methods
developed, it will be important to validate the instrument. This will be achieved by
comparing collected ion mobility, HDX, and scrambling data from the new instrument to
literature values [41–45].

Additionally, it would be worthwhile to compare the

performance of the new instrument and strategy to currently used LC-MS/MS methods.
Performance of the two methods will be compared in terms of the total analysis time, the
number of proteins, peptides, and metabolites identified, and the accuracy of the
identifications.
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